

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF NORTH CAROLINA
SOUTHERN DIVISION**

BRENT NIX, individually and on behalf of all others
similarly situated,

Plaintiff,

v.

THE CHEMOURS COMPANY FC, LLC, THE
CHEMOURS COMPANY, E.I. DUPONT de
NEMOURS AND COMPANY, INC., E.I. DUPONT
CHEMICAL CORPORATION, ELLIS H.
MCGAUGHY, and MICHAEL E. JOHNSON,

Defendant.

Civil Action No. 7:17-CV-00189-D

ROGER MORTON, individually and on behalf of all
others similarly situated,

Plaintiff,

v.

THE CHEMOURS COMPANY FC, LLC, THE
CHEMOURS COMPANY, E.I. DUPONT de
NEMOURS AND COMPANY, INC., E.I. DUPONT
CHEMICAL CORPORATION, ELLIS H.
MCGAUGHY, AND MICHAEL E. JOHNSON;

Defendants.

Civil Action No. 7:17-cv-00197-D

VICTORIA CAREY, MARIE BURRIS, MICHAEL
KISER, and BRENT NIX, individually and on behalf
of all others similarly situated,

Plaintiffs,

v.

E.I. DUPONT de NEMOURS AND COMPANY and
THE CHEMOURS COMPANY FC, LLC,
Defendants.

Civil Action No. 7:17-CV-00201-D

UNITED STATES DISTRICT COURT

for the

Eastern District of North Carolina

Carey, et al.

Plaintiff

v.

E.I. du Pont de Nemours & Co., et al.

Defendant

Civil Action No. 7:17-cv-00189-D

SUBPOENA TO PRODUCE DOCUMENTS, INFORMATION, OR OBJECTS OR TO PERMIT INSPECTION OF PREMISES IN A CIVIL ACTION

To: U.S. Environmental Protection Agency, c/o Leif Palmer (Regional Counsel), Sam Nunn Atlanta Federal Center 61
Forsyth St. SW #9, Atlanta, GA 30303

(Name of person to whom this subpoena is directed)

☒ **Production:** **YOU ARE COMMANDED** to produce at the time, date, and place set forth below the following documents, electronically stored information, or objects, and to permit inspection, copying, testing, or sampling of the material:

Place: Perry Law Firm, LLC
1493 LaVista Road NE
Atlanta, GA 30324

Date and Time:

04/09/2020 9:00 am

☐ **Inspection of Premises:** **YOU ARE COMMANDED** to permit entry onto the designated premises, land, or other property possessed or controlled by you at the time, date, and location set forth below, so that the requesting party may inspect, measure, survey, photograph, test, or sample the property or any designated object or operation on it.

Place:

Date and Time:

The following provisions of Fed. R. Civ. P. 45 are attached – Rule 45(c), relating to the place of compliance; Rule 45(d), relating to your protection as a person subject to a subpoena; and Rule 45(e) and (g), relating to your duty to respond to this subpoena and the potential consequences of not doing so.

Date: 3/10/20

CLERK OF COURT

OR

Signature of Clerk or Deputy Clerk

Jani Bowers
Attorney's Signature

The name, address, e-mail address, and telephone number of the attorney representing (name of party) Marie Burris,
Victoria Carey, Michael Kiser, and Brent Nix, who issues or requests this subpoena, are:

Jamie Bowers, 1100 New York Ave. NW, Washington, DC 20005; jbowers@cohenmilstein.com; (202) 408-4670

Notice to the person who issues or requests this subpoena

If this subpoena commands the production of documents, electronically stored information, or tangible things or the inspection of premises before trial, a notice and a copy of the subpoena must be served on each party in this case before it is served on the person to whom it is directed. Fed. R. Civ. P. 45(a)(4).

Civil Action No. 7:17-cv-00189-D

PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 45.)

I received this subpoena for *(name of individual and title, if any)* _____
on *(date)* _____.

☐ I served the subpoena by delivering a copy to the named person as follows: _____

_____ on *(date)* _____; or

☐ I returned the subpoena unexecuted because: _____

Unless the subpoena was issued on behalf of the United States, or one of its officers or agents, I have also
tendered to the witness the fees for one day's attendance, and the mileage allowed by law, in the amount of
\$ _____.

My fees are \$ _____ for travel and \$ _____ for services, for a total of \$ _____ 0.00.

I declare under penalty of perjury that this information is true.

Date: _____
_____ *Server's signature*

Printed name and title

Server's address

Additional information regarding attempted service, etc.:

Federal Rule of Civil Procedure 45 (c), (d), (e), and (g) (Effective 12/1/13)**(c) Place of Compliance.**

(1) For a Trial, Hearing, or Deposition. A subpoena may command a person to attend a trial, hearing, or deposition only as follows:

- (A) within 100 miles of where the person resides, is employed, or regularly transacts business in person; or
- (B) within the state where the person resides, is employed, or regularly transacts business in person, if the person
 - (i) is a party or a party's officer; or
 - (ii) is commanded to attend a trial and would not incur substantial expense.

(2) For Other Discovery. A subpoena may command:

- (A) production of documents, electronically stored information, or tangible things at a place within 100 miles of where the person resides, is employed, or regularly transacts business in person; and
- (B) inspection of premises at the premises to be inspected.

(d) Protecting a Person Subject to a Subpoena; Enforcement.

(1) Avoiding Undue Burden or Expense; Sanctions. A party or attorney responsible for issuing and serving a subpoena must take reasonable steps to avoid imposing undue burden or expense on a person subject to the subpoena. The court for the district where compliance is required must enforce this duty and impose an appropriate sanction—which may include lost earnings and reasonable attorney's fees—on a party or attorney who fails to comply.

(2) Command to Produce Materials or Permit Inspection.

(A) Appearance Not Required. A person commanded to produce documents, electronically stored information, or tangible things, or to permit the inspection of premises, need not appear in person at the place of production or inspection unless also commanded to appear for a deposition, hearing, or trial.

(B) Objections. A person commanded to produce documents or tangible things or to permit inspection may serve on the party or attorney designated in the subpoena a written objection to inspecting, copying, testing, or sampling any or all of the materials or to inspecting the premises—or to producing electronically stored information in the form or forms requested. The objection must be served before the earlier of the time specified for compliance or 14 days after the subpoena is served. If an objection is made, the following rules apply:

- (i) At any time, on notice to the commanded person, the serving party may move the court for the district where compliance is required for an order compelling production or inspection.
- (ii) These acts may be required only as directed in the order, and the order must protect a person who is neither a party nor a party's officer from significant expense resulting from compliance.

(3) Quashing or Modifying a Subpoena.

(A) When Required. On timely motion, the court for the district where compliance is required must quash or modify a subpoena that:

- (i) fails to allow a reasonable time to comply;
- (ii) requires a person to comply beyond the geographical limits specified in Rule 45(c);
- (iii) requires disclosure of privileged or other protected matter, if no exception or waiver applies; or
- (iv) subjects a person to undue burden.

(B) When Permitted. To protect a person subject to or affected by a subpoena, the court for the district where compliance is required may, on motion, quash or modify the subpoena if it requires:

- (i) disclosing a trade secret or other confidential research, development, or commercial information; or

(ii) disclosing an unretained expert's opinion or information that does not describe specific occurrences in dispute and results from the expert's study that was not requested by a party.

(C) Specifying Conditions as an Alternative. In the circumstances described in Rule 45(d)(3)(B), the court may, instead of quashing or modifying a subpoena, order appearance or production under specified conditions if the serving party:

- (i) shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship; and
- (ii) ensures that the subpoenaed person will be reasonably compensated.

(e) Duties in Responding to a Subpoena.

(1) Producing Documents or Electronically Stored Information. These procedures apply to producing documents or electronically stored information:

(A) Documents. A person responding to a subpoena to produce documents must produce them as they are kept in the ordinary course of business or must organize and label them to correspond to the categories in the demand.

(B) Form for Producing Electronically Stored Information Not Specified. If a subpoena does not specify a form for producing electronically stored information, the person responding must produce it in a form or forms in which it is ordinarily maintained or in a reasonably usable form or forms.

(C) Electronically Stored Information Produced in Only One Form. The person responding need not produce the same electronically stored information in more than one form.

(D) Inaccessible Electronically Stored Information. The person responding need not provide discovery of electronically stored information from sources that the person identifies as not reasonably accessible because of undue burden or cost. On motion to compel discovery or for a protective order, the person responding must show that the information is not reasonably accessible because of undue burden or cost. If that showing is made, the court may nonetheless order discovery from such sources if the requesting party shows good cause, considering the limitations of Rule 26(b)(2)(C). The court may specify conditions for the discovery.

(2) Claiming Privilege or Protection.

(A) Information Withheld. A person withholding subpoenaed information under a claim that it is privileged or subject to protection as trial-preparation material must:

- (i) expressly make the claim; and
- (ii) describe the nature of the withheld documents, communications, or tangible things in a manner that, without revealing information itself privileged or protected, will enable the parties to assess the claim.

(B) Information Produced. If information produced in response to a subpoena is subject to a claim of privilege or of protection as trial-preparation material, the person making the claim may notify any party that received the information of the claim and the basis for it. After being notified, a party must promptly return, sequester, or destroy the specified information and any copies it has; must not use or disclose the information until the claim is resolved; must take reasonable steps to retrieve the information if the party disclosed it before being notified; and may promptly present the information under seal to the court for the district where compliance is required for a determination of the claim. The person who produced the information must preserve the information until the claim is resolved.

(g) Contempt.

The court for the district where compliance is required—and also, after a motion is transferred, the issuing court—may hold in contempt a person who, having been served, fails without adequate excuse to obey the subpoena or an order related to it.

Attachment A

ATTACHMENT A

DEFINITIONS

As used in Attachment B, the following terms have the meanings set forth below:

1. “You,” “Your,” and “EPA” refer to the U.S. Environmental Protection Agency, headquartered at 1200 Pennsylvania Ave. NW, Washington, D.C. 20460.

2. “Chemours” means the Chemours Company FC, LLC, a Delaware limited liability company with its principal place of business located at 1007 Market St., Wilmington, DE 19898, and includes: any division, branch, department, or subsidiary of Chemours; the present and former employees, directors, officers, accountants, affiliates, attorneys, partners, managers, agents, representatives, in-house and outside counsel or other persons (including consultants) under the control of Chemours; and any other person acting or purporting to act on behalf of Chemours.

“DuPont” means E.I. du Pont de Nemours and Company, a Delaware corporation, with its principal place of business located at 1007 Market St., Wilmington, DE 19898, and includes: any division, branch, department, or subsidiary of DuPont; the present and former employees, directors, officers, accountants, affiliates, attorneys, partners, managers, agents, representatives, in-house and outside counsel or other persons (including consultants) under the control of DuPont; and any other person acting or purporting to act on behalf of DuPont.

3. “Defendants” means DuPont and Chemours, the named Defendants in the above-captioned cases.

4. “Document” is used in the broadest sense to mean anything which may be within the meaning of Rule 34 of the Federal Rules of Civil Procedure, and includes without limitation any written, printed, typed, photocopied, photographed, recorded or otherwise reproduced or stored communication or representation, whether comprised of letters, words, numbers, data,

pictures, sounds or symbols, or any combination thereof. The word “document” includes without limitation, correspondence, memoranda, notes, records, letters, envelopes, telegrams, messages, studies, analyses, contracts, agreements, working papers, accounts, analytical records, reports and/or summaries of investigations, press releases, comparisons, books, calendars, diaries, articles, magazines, newspapers, booklets, brochures, pamphlets, circulars, bulletins, notices, drawings, diagrams, instructions, notes of minutes of meetings or communications, electronic mail/messages and/or “e-mail,” text messages, social media communications, voice mail messages, instant messaging, questionnaires, surveys, charts, graphs, photographs, films, tapes, disks, data cells, print-outs of information stored or maintained by electronic data processing or word processing equipment, all other data compilations from which information can be obtained (by translation, if necessary, by You through detection devices into usable form), including, without limitation, electromagnetically sensitive storage media such as CDs, DVDs, memory sticks, floppy disks, hard disks and magnetic tapes, and any preliminary versions, as well as drafts or revisions of any of the foregoing.

5. “Fayetteville Works” means the industrial facility located at 22828 N.C. Highway 87 W., Fayetteville, NC 28306. “Fayetteville Works” refers to and includes any entity owning or responsible for operating, leasing from, operating within, or otherwise employed or working at the facility, including, but not limited to, Chemours and DuPont.

6. “GenX” means a polyfluorinated chemical bearing Chemical Abstracts Service (“CAS”) Number 13252-13-6, as well as the ammonium salt of HFPO-DA, or “GenX,” bearing CAS Number 62037-80-3. GenX also refers to and includes C-3 Dimer Acid generated as a waste of the vinyl ether manufacturing process.

7. “PFAS” means polyfluorinated chemicals and includes, but is not limited to, perfluorocarboxylic acids (“PFCAs”), perfluorooctanoic acids (“PFOAs” or “C8”) (including ammonium perfluorooctonate (“AFPO”)), perfluoroalkyl ether carboxylic acids with one ether group (“mono-ether PFECAs”), perfluoroalkyl ether carboxylic acids with multiple ether groups (“multi-ether PFECAs”), perfluorooctane sulfonate (“PFOS”), perfluoro-2-propoxypropanoic acid (“PFPrOPrA”), Nafion, Nafion wastes, and perfluorosulfonic acids (“PFSAs”). The full list of PFAS relevant to these requests is attached as Exhibit A.

8. “Regarding” or “relating to” means concerning, pertaining to, referring to, describing, discussing, memorializing, reflecting, containing, evidencing, or constituting.

9. “Relevant Time Period” means from 1980 to present day. Unless otherwise stated, all document requests refer to documents created or in effect during the Relevant Time Period.

INSTRUCTIONS

10. The requests below are intended to impose minimal burden on You. If you have questions regarding how to comply with the requests, or if you have any issue understanding these requests, please call Jamie Bowers at Cohen Milstein Sellers & Toll PLLC (202-408-4670) to discuss.

11. In the event You are able to produce only some of the documents called for in a particular request, please produce all the documents You are able to and state the reasons for Your inability to produce the remainder.

12. If You object to a portion of a request, please produce all documents called for by that portion of the request to which You do not object.

Attachment B

ATTACHMENT B

CATEGORIES OF DOCUMENTS TO BE PRODUCED

1. All human or animal health studies concerning GenX or other PFAS listed in Exhibit A.
2. All notifications sent to the EPA by DuPont and/or Chemours concerning any human or animal health studies, environmental investigations, and/or environmental reports relating to GenX or other PFAS listed in Exhibit A.
3. All documents and data recording, reporting, detailing, or describing spills, air emissions, leaks, or wastewater discharges of GenX and/or other PFAS listed in Exhibit A from Fayetteville Works.
4. All documents, interrogatory answers (including interrogatories), and/or other materials produced in response to an EPA subpoena or other EPA investigative process by Chemours or DuPont relating to the discharge of GenX or other PFAS listed in Exhibit A from Fayetteville Works.
5. All documents filed by Fayetteville Works with the EPA relating to the Toxic Substances Control Act (including but not limited to Section 5(e) consent order submissions, laboratory testing or analysis conducted pursuant to Section 5(e) consent orders, submissions under significant new use rule notices, and submissions under pre-manufacture notices) and GenX and/or other PFAS listed in Exhibit A.
6. All documents sent to Fayetteville Works from the EPA relating to the Toxic Substances Control Act (including but not limited to Section 5(e) consent orders, significant new use rule notices, and pre-manufacture notices) and GenX and/or other PFAS listed in Exhibit A.
7. All documents submitted to the EPA by DuPont or Chemours relating to or as any part of any application for a Clean Air Act permit for Fayetteville Works, including but not limited to any

emissions reports, data, emissions monitoring reports, or notices of instances of alleged or actual violations or non-compliance.

8. All Clean Air Act Title V permits issued by the EPA relating to Fayetteville Works.

9. All notices of violations issued by the EPA to Chemours or DuPont relating to Fayetteville Works National Pollutant Discharge Elimination System permit or Clean Air Act permit.

10. Any and all communications between employees or agents of the EPA and employees or agents of DuPont and/or Chemours relating to GenX or other PFAS listed in Exhibit A and not produced in response to the other requests herein.

11. Any correspondence concerning any PFAS listed in Exhibit A between the EPA and: (a) other administrative agencies or members of the Executive Branch; (b) any members of Congress or their staff; or (c) 3M Company.

12. The results of any tests designed to detect any PFAS listed in Exhibit A in the Cape Fear River or in the following North Carolina counties: Bladen, Brunswick, Columbus, Cumberland, New Hanover, and Pender.

Exhibit A

EPA 537 mod. PFCs by LC-MS/MS	CASRN	Acronym
2,3,3,3-Tetrafluoro-2- (1,1,2,2,3,3,3-heptafluoropropoxy)- propanoic acid	13252-13-6	PFPrOPrA/GenX (HFPO-DA)
Perfluorobutanesulfonate	375-73-5	PFBS
Perfluorobutyric acid	375-22-4	PFBA
Perfluorodecanoic acid	335-76-2	PFDA
Perfluoroheptanoic acid	375-85-9	PFHpA
Perfluorohexadecanoic acid	67905-19-5	PFHxDA
Perfluorohexanesulfonate	355-46-4	PFHxS
Perfluorohexanoic acid	307-24-4	PFHxA
Perfluorononanoic acid	375-95-1	PFNA
Perfluorooctadecanoic acid	16517-11-6	PFODA
Perfluorooctanesulfonate	1763-23-1	PFOS
Perfluorooctanoic acid	335-67-1	PFOA
Perfluoropentanesulfonate	2706-91-4	PFPeS
Perfluoropentanoic acid	2706-90-3	PFPeA
Perfluoro-2-methylethoxyacetic acid	151772-58-6	PFMOEA
Perfluoro-n-undecanoic acid	2058-94-8	PFUdA/PFUnA
Perfluoro-n-dodecanoic acid	307-55-1	PFDoA
Perfluoro-n-tridecanoic acid	72629-94-8	PFTTrDA/PFTnA
Perfluoro-n-tetradecanoic acid	376-06-7	PFTeDA/PFTeA
Sodium perfluoro-1-decanesulfonate	335-77-3	L-PFDS/PFDS
NC 6 PFCs by LC-MS/MS (EPA 537 mod.)		
Nafion Byproduct 1	29311-67-9	NB-1
Nafion Byproduct 2	749836-20-2	NB-2
Perfluoro-3-methoxypropanoic acid	377-73-1	PFMOPrA
Perfluoro-4-methoxybutanic acid	863090-89-5	PFMOBA
Perfluoro(3,5,7,9-tetraoxadecanoic) acid	39492-90-5	PFO4DA
Perfluoro(3,5,7-trioxaoctanoic) acid	39492-89-2	PFO3OA
Perfluoro(3,5-dioxahexanoic) acid	39492-88-1	PFO2HxA
Perfluoro-2-methoxyacetic acid	674-13-5	PFMOAA
Sodium 2,2,4,4,6,6,8,8,10,10,12,12,12-tridecafluoro-3,5,7,9,11-pentaoxadodecanoate	39492-91-6	TAF n=4

PFASs by LC-MS/MS (Chemours Method, Table 3 SOP)		
2,3,3,3-Tetrafluoro-2- (1,1,2,2,3,3,3-heptafluoropropoxy)- propanoic acid	13252-13-6	PFPrOPrA/GenX (HFPO-DA)
Nafion Byproduct 1	29311-67-9	PFESA/NB-1
Nafion Byproduct 2	749836-20-2	PFESA/NB-2
Perfluoro(3,5,7,9-tetraoxadecanoic) acid	39492-90-5	PFO4DA
Perfluoro(3,5,7-trioxaoctanoic) acid	39492-89-2	PFO3OA
Perfluoro(3,5-dioxahexanoic) acid	39492-88-1	PFO2HxA
Perfluoro-2-methoxyacetic acid	674-13-5	PFMOAA
Sodium 2,2,4,4,6,6,8,8,10,10,12,12,12-tridecafluoro-3,5,7,9,11-pentaoxadodecanoate	39492-91-6	TAF n=4

Attachment C

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF NORTH CAROLINA
SOUTHERN DIVISION**

VICTORIA CAREY, MARIE BURRIS,)
MICHAEL KISER, and BRENT NIX,)
individually and on behalf of all others)
similarly situated,)

Plaintiff,)

v.)

E. I. DU PONT DE NEMOURS AND)
COMPANY and THE CHEMOURS)
COMPANY FC, LLC,)

Defendants.)
_____)

Case Nos.: 7:17-CV-00189
7:17-CV-00197
7:17-CV-00201

FIRST AMENDED CONSOLIDATED
CLASS ACTION COMPLAINT

JURY DEMAND

TABLE OF CONTENTS

	Page
I. INTRODUCTORY STATEMENT	1
II. JURISDICTION AND VENUE.....	3
III. PARTIES	4
A. Plaintiffs	4
B. Defendants	4
IV. STATEMENT OF FACTS	5
A. Fayetteville Works	5
B. The Pollutants: GenX and other PFCs	6
C. Defendants Conceal the Harmful Effects of GenX and Related Contaminants	7
D. Defendants' Toxic Discharges to the Cape Fear River and Air Emissions Come to Light	24
E. Remediation of Buildup of GenX, Nafion Wastes, and Related Contaminants in Residential Plumbing Requires Plumbing and Fixture Replacement.....	33
F. Plaintiffs' Experiences	34
V. CLASS ALLEGATIONS.....	37
A. Class Claims.....	37
COUNT I: NEGLIGENCE.....	40
COUNT II: GROSS NEGLIGENCE.....	42
COUNT III: NEGLIGENCE PER SE: BY ALL PLAINTIFFS AGAINST DEFENDANTS	43
COUNT IV: PUBLIC AND PRIVATE NUISANCE: BY ALL PLAINTIFFS AGAINST DEFENDANTS	44
COUNT V: TRESPASS BY ALL PLAINTIFFS AGAINST DEFENDANTS.....	45
COUNT VI: UNJUST ENRICHMENT	46
PRAYER FOR RELIEF	47
DEMAND FOR TRIAL BY JURY	47

GLOSSARY

Defined Term	Definition
APFO	Ammonium perfluorooctonate, the ammonium salt of PFOA (also known as “C8”)
CDC	U.S. Centers for Disease Control and Prevention
CFPUA	Cape Fear Public Utility Authority
CFPUA Notice	Notice of intent to sue sent to DuPont by the CFPUA dated August 3, 2017
Chemours	The Chemours Company FC, LLC
Class	All persons who from February 1, 2015 to the present lived within New Hanover, Brunswick, Bladen, Cumberland, or Pender Counties, or who currently own property or businesses there.
Consent Order	Consent order entered into by DuPont and the EPA on January 28, 2009, governing the manufacturing of GenX
Defendants	DuPont and Chemours
DENR	North Carolina Department of Environment and Natural Resources
DEQ	North Carolina Department of Environmental Quality
DHHS	North Carolina Department of Health and Human Services
DuPont	E. I. du Pont de Nemours and Company
DWQ	North Carolina Division of Water Quality
DWR	North Carolina Division of Water Resources
EPA	U.S. Environmental Protection Agency
Fayetteville Works	DuPont’s Fayetteville Works industrial facility, located at 22828 NC Highway 87 W, Fayetteville, North Carolina 28306.
Gen-X (C-3 Dimer)	A replacement chemical to be used after the phase-out of PFOAs
GenX Report	A 2014 report entitled: “Evaluation of chronic toxicity and carcinogenicity of ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate in Sprague–Dawley rats”
HAL	Health Advisory Level
Mono-ether PFECAs	Perfluoroalkyl ether carboxylic acids with one ether group
Multi-ether PFECAs	Perfluoroalkyl ether carboxylic acids with multiple ether groups
Non-neoplastic	New growth in tissue that does not serve a useful purpose – <i>i.e.</i> , tumors.
NPDES	National Pollutant Discharge Elimination System
NPDES Permit	Fayetteville Works Facility NPDES Permit No. NC0003573
PFASs	Polyfluorinated substances

PFCs	Polyfluorinated chemicals
PFCAs	Perfluorocarboxylic acids
PFOAs	Perfluorooctanoic acids, also known as “C8”
PFOS	Perfluorooctane sulfonate
PFPrOPrA	Perfluoro-2-propoxypropanoic acid
PFSAs	Perflurosulfonic acids
Plaintiffs	Victoria Carey, Marie Burris, Mike Kiser, and Brent Nix
PPA	Polymer Processing Aid
PPAR α agonists	peroxisome proliferators
PVF	Polyvinyl Fluoride
RCRA	Resource Conservation and Recovery Act
RFI	RCRA Facility Investigation
SWMUs	Solid Waste Management Units

I. INTRODUCTORY STATEMENT

1. For nearly four decades, Defendants have willfully and wantonly, recklessly, and negligently discharged toxic, cancer-causing chemicals into the Cape Fear River, the primary source of drinking water for thousands of North Carolina residents. From 1980 to the present, Defendants have operated the Fayetteville Works chemical plant, which has discharged wastewater containing polyfluorinated chemicals such as GenX (collectively referred to as “PFCs”)¹ into the Cape Fear River. Throughout, Defendants knew that these chemicals were extremely dangerous: even very small doses could cause liver, testicular, pancreatic, uterine and kidney cancer, as well as thyroid disease, ulcerative colitis and pregnancy-induced hypertension, among other illnesses. Nevertheless, Defendants dumped these chemicals into the air and water surrounding the Fayetteville Works plant, simply to avoid the expense of taking safety precautions. Knowing that their conduct was illegal and wrong, Defendants lied to government regulators, claiming that they were disposing of PFCs at a secure, off-site facility, or incinerating them. Defendants’ lies about the way that they were disposing of a PFC called GenX and other PFCs associated with Defendants’ manufacturing processes were particularly harmful: Because neither the state nor local water providers knew that Defendants were discharging GenX and other PFCs into the local water supply, they could not and did not design water filters to keep families from drinking dangerous amounts of GenX and other PFCs.

2. The impact on counties that use the Cape Fear River as a primary source of drinking water—New Hanover, Bladen, Brunswick, Cumberland, and Pender Counties in North Carolina—has been devastating. Bladen, Brunswick, Pender, and New Hanover Counties have

¹ PFC is a broad term encompassing all polyfluorinated chemicals, including but not limited to the chemicals listed in Appendix A.

among the highest concentrations of liver disease in the United States.² In addition, the rate of liver and testicular cancers in New Hanover County is significantly higher than the state average, the rate of kidney cancer in Bladen County is significantly higher than the state average, the rate of pancreatic cancer in Brunswick County is significantly higher than the state average, and the rate of uterine cancer in Cumberland County is significantly higher than the state average.³

3. There is no “quick fix” for these dire consequences. The chemicals have spread throughout more than 100 miles of the Cape Fear River and tens of thousands of miles of municipal and residential piping, where they have bonded with pipes, microbes, plants, animals, and sediments which will slowly release the chemicals back into the water supply for decades. They have also been emitted into the atmosphere and settled over more than 1000 square miles.

4. But if the chemicals are not removed quickly, thousands more individuals could develop PFAS-related illness. According to the 2016 U.S. Census, Bladen, Brunswick, Pender, and New Hanover Counties have a combined population of 774,394 individuals who occupy 362,585 housing units.

5. This is a class action on behalf of the thousands of residents, property owners, and business owners who have experienced, and will continue to experience, serious harm from Defendants’ conduct. Because recent studies confirm that Defendants’ PFCs are already in the blood of individuals living in the affected counties, Plaintiffs are seeking relief on a class-wide basis for the costs of future medical care to identify and treat diseases caused by those

² Multiple cause of death data published by the U.S. Centers for Disease Control and Prevention (“CDC”).

³ Central registry of the North Carolina Department of Health and Human Services (“DHHS”).

contaminants⁴; the costs of bottled water and filtration systems (including upkeep and maintenance) needed to avoid additional exposure to Defendants' PFCs; the cost of cleaning and replacing contaminated plumbing, fixtures, and appliances; loss of use and enjoyment of contaminated property; and the reduced value of property and businesses. Plaintiffs are seeking monetary damages and injunctive relief to address these past, present and future injuries.

6. Plaintiffs additionally seek class certification of specific issues relating to past and present personal injuries—beyond blood contamination—resulting from exposure to Defendants' PFCs. While Plaintiffs are not seeking redress for specific illnesses or loss of life caused by PFC exposure on a class-wide basis, there are a number of important threshold issues relating to personal injury claims that are common to individuals exposed to PFCs from Fayetteville Works and that are thus being pursued on a class-wide basis.

II. JURISDICTION AND VENUE

7. The Court has diversity jurisdiction under 28 U.S.C. § 1332(d). This is a class action in which Plaintiffs are citizens of the State of North Carolina, and Defendants are citizens of the State of Delaware. There are more than one hundred putative Class members, seeking damages that exceed \$5,000,000.00, exclusive of interest and costs.

8. The Court has personal jurisdiction over Defendants because each of them has personally availed itself of the benefits and protections of the laws of the State of North Carolina. Each of the Defendants conducted business and committed torts in North Carolina, by itself or through an agent or *alter ego*, which caused Plaintiffs and Class members to suffer severe personal

⁴ On April 19, 2019, the Court granted Defendants' motion to dismiss Plaintiffs' request for medical monitoring, but held that Plaintiffs could recover "future medical expenses" for their current injuries. By referencing future medical expenses in this Amended Complaint, Plaintiffs are *not* asking the Court to reconsider its April 19 decision; rather, consistent with the Court's order, Plaintiffs are seeking compensation for "future medical expenses" flowing from current contamination of their blood.

and property injuries in the state.

9. Venue is proper in this Court because the original injury and damage occurred in the Eastern District of North Carolina and Defendants conduct business in the Eastern District of North Carolina. Plaintiffs reside or resided in the Eastern District of North Carolina and/or own property located in the Eastern District of North Carolina that was damaged, and many of the occurrences described herein occurred in the Eastern District of North Carolina.

III. PARTIES

A. Plaintiffs

10. Plaintiff **Victoria Carey** is a citizen of North Carolina, residing at 8256 Egret Pointe NE, Leland, North Carolina 28451.

11. Plaintiff **Dr. Marie Burris** is a citizen of North Carolina, residing at 14 Botanical Court, Bunnlevel, North Carolina 28323. She owns property at 21158 NC Highway 87 W, Fayetteville, North Carolina 28306.

12. Plaintiff **Michael E. Kiser** is a citizen of North Carolina, residing at 4421 Jay Bird Circle, Unit 207, Wilmington, North Carolina 28412.

13. Plaintiff **Brent Nix** is a citizen of North Carolina, residing at 5008 Laurenbridge Lane, Wilmington, North Carolina 28409.

B. Defendants

14. Defendant **E. I. du Pont de Nemours and Company** (“DuPont”) is a Delaware corporation, with its principal place of business located at 1007 Market Street, Wilmington, Delaware 19898. DuPont is a multinational chemical manufacturer. It owned the Fayetteville Works industrial facility, located at 22828 NC Highway 87 W, Fayetteville, North Carolina 28306 (“Fayetteville Works”), from the early 1970s until February 1, 2015, during which time it disposed

of PFCs into the Cape Fear River. DuPont still operates a manufacturing area at Fayetteville Works.

15. **Defendant The Chemours Company FC, LLC** (“Chemours”) is a Delaware Limited Liability Company, with its principal place of business located at 1007 Market Street, Wilmington, Delaware 19898. Chemours is a multinational chemical manufacturer. Chemours, including its assets and liabilities, was wholly owned by DuPont when Chemours acquired Fayetteville Works from DuPont on February 1, 2015. Chemours later separated from DuPont in July 2015. During the time Chemours has owned and operated Fayetteville Works, it has discharged PFCs into the Cape Fear River.

IV. STATEMENT OF FACTS

A. Fayetteville Works

16. The Fayetteville Works chemical plant produces a variety of films, fibers, and specialty chemicals. The plant is enormous, spanning 2,150 acres. For years, Fayetteville Works has had at least five discrete manufacturing areas: (i) fluoromonomers/Nafion; (ii) polymer processing aid (“PPA”); (iii) Butacite; (iv) SentryGlas; and (v) polyvinyl fluoride (“PVF”).

17. The wastewater from each of the five manufacturing areas flows through one or more on-site wastewater treatment plants, where the contaminated waste water is diluted with hundreds of thousands of gallons of river water before it is ultimately discharged into the Cape Fear River. This dilution makes PFCs harder to detect, but does not ultimately reduce the amount of PFCs flowing into the Cape Fear River.

18. Fayetteville Works is operating under National Pollutant Discharge Elimination System (“NPDES”) Permit No. NC0003573 (the “NPDES Permit”).

B. The Pollutants: GenX and other PFCs

19. The Fayetteville Works plant discharged a group of synthetic chemical compounds called polyfluorinated or perfluorinated chemicals, or simply PFCs. PFCs are used in manufacturing Teflon, as well as other fire-resistant, stain-resistant, and water-resistant products.

20. In particular, Defendants have manufactured and discharged the following PFCs: GenX, perfluorocarboxyl acids (“PFCAs”), perflurosulfonic acids (“PFSAs”), perfluoroalkyl ether carboxylic acids with one ether group (“mono-ether PFECAs”), perfluoroalkyl ether carboxylic acids with multiple ether groups (“multi-ether PFECAs”), perfluorooctanoic acids (“PFOAs”) (including ammonium perfluorooctonate (“APFO”)), perfluorooctane sulfonate (“PFOS”), Perfluoro-2-propoxypropanoic acid (“PFPrOPrA”), Nafion, and Nafion wastes and other wastes and breakdown products of these chemicals (some of which are called legacy and emerging PFCs).

21. PFCs are highly toxic to humans. Scientists have linked PFCs to kidney cancer, testicular cancer, prostate cancer, ovarian cancer, non-Hodgkin lymphoma, liver disease, ulcerative colitis, thyroid disease, hypercholesterolemia, and pregnancy-induced hypertension, among other illnesses.

22. In light of the dangers posed by PFCs, the U.S. Environmental Protection Agency (“EPA”) recently established a lifetime health advisory level (“HAL”) of 70 ng/L (parts per trillion or “ppt”) for the sum of the PFOA and PFOS concentrations in drinking water. The State of North Carolina has adopted a preliminary health-based standard of 140 ppt for GenX. This preliminary standard will likely be lowered in the future to account for the risk that GenX causes cancer and to account for any special harm that GenX may present to vulnerable populations such as children and individuals exposed to multiple PFCs.

23. Moreover, PFCs are extremely difficult to remediate because they are not biodegradable. “Long-chain PFCs”—so called because they have six or more carbon atoms—can

persist in the environment for over 2,000 years. PFOAs, which were discharged from Fayetteville Works beginning in 1980 and continuing through 2009, are C8s, with 8 carbon atoms. Other PFCs associated with Defendants' manufacturing processes and discharged from Fayetteville Works, including Nafion byproducts 1 and 2, are C7s, with seven carbon atoms. And even "shorter chain" PFCs do not biodegrade quickly. A recent DuPont study found that GenX—a mid-length PFC, with 6 carbon atoms—biodegraded by less than one percent after 28 days. Other studies have confirmed that long-chain PFCs and their short-chain alternatives are "equally persistent."⁵

24. Moreover, it is extremely difficult to clean air, water, or property contaminated by PFCs because the chemicals bond with proteins in the cells of living organisms and adhere to sediment, scale and pipes. Thus, current drinking water filtration systems cannot remove PFCs effectively. Scientists are beginning to build and test reverse osmosis systems that might be able to filter PFCs from water, but they have not collected enough data to know whether those systems will be effective over long periods of time.

25. That is extremely troubling, because PFCs can persist in the human body for decades. For example, when PFOA is ingested, it stays in human blood for 25 years. Because the human body cannot get rid of PFCs, they accumulate over time. As a result, even if someone drinks water with extremely low levels of PFCs, the chemicals can slowly build to toxic levels in that person's blood. This slow accumulation of PFCs has harmed thousands of North Carolina residents, some of whom have been drinking PFC-laden water for more than 30 years.

C. Defendants Conceal the Harmful Effects of GenX and Related Contaminants

26. From the 1950s to the early 2000s, DuPont relied heavily on PFOA—a long-chain PFC with 8 carbon atoms—to make Teflon and other non-stick products. Throughout this period,

⁵ Gomis, et al, Env. Intern. 113 (2018) at 2.

DuPont conducted a robust collection of animal studies, which strongly suggested that PFOA might be toxic. At the same time, DuPont conducted a smaller—but still significant—set of studies demonstrating that humans exposed to PFOA developed a variety of illnesses. Despite the clear warning signs that DuPont received from its data, it disposed of PFOA in drinking water near its plants in North Carolina and West Virginia, rather than paying to take safety precautions. DuPont also lied to both West Virginia and North Carolina regulators to hide the fact that it was endangering local families. In 2015, as part of a settlement with West Virginia residents, an expert panel of epidemiologists determined that, by discarding PFOA into drinking water, DuPont caused West Virginians to develop kidney cancer, testicular cancer, ulcerative colitis, thyroid disease, hypercholesterolemia, and pregnancy-induced hypertension.

27. History is now repeating itself. Since the 1980s, DuPont has used not just PFOA, but GenX and similar PFCs at its Fayetteville Works plant. In the early 2000s, when government regulators pressured DuPont to stop using PFOA in its manufacturing processes, DuPont began to replace PFOA with its close chemical cousin, GenX. But GenX might be even more toxic than PFOA.⁶ In addition, DuPont has continued to discharge Nafion byproducts 1 and 2, long-chain C7 PFCs produced only by Defendants, which have toxicity characteristics that are similar to PFOA. Overlooking the results of its own toxicity studies, DuPont has discharged GenX, Nafion byproducts 1 and 2, and other PFCs into the Cape Fear River, showing the same cold disregard for human health that it showed when it discharged PFOA. And, just as it did with PFOA, DuPont has concealed its dangerous discharge practices from government regulators. Plaintiffs are now paying the price for Defendants' failure to learn from their mistakes. GenX—together with Nafion

⁶ Gomis, et al, Env. Intern. 113 (2018) at 1 (“The toxicity ranking using modeled serum (GenX > PFOA > PFHxA > PFBA) and liver (GenX > PFOA≈PFHxA≈PFBA) concentrations indicated that some fluorinated alternatives have similar or higher toxic potency than their predecessors when correcting for differences in toxicokinetics.”)

byproducts 1 and 2 and the other PFCs that Defendants have been dumping into the Cape Fear River for decades—is devastating local families and businesses.

1. DuPont’s History with PFOA

28. Since the 1960s, DuPont has worked to conceal a bevy of scientific evidence suggesting that PFOA is harmful to human health.

29. In 1961, DuPont researchers conducted the first safety test of PFOA, administering PFOA to rodents. The researchers noted that the rodents had enlarged livers—a classic response to poison—and recommended further testing.

30. In 1962, DuPont performed a second safety test of PFOA and found that rodents exposed to PFOA had enlarged livers, kidneys, adrenal glands, and testes. That same year, DuPont asked human subjects to smoke cigarettes laced with PFOA and observed, “Nine out of ten people in the highest-dosed group were noticeably ill for an average of nine hours with flu-like symptoms that included chills, backache, fever, and coughing.”

31. In 1966, DuPont researchers discovered that PFOA was toxic to fish.

32. These toxicity tests prompted DuPont staff to consider safe mechanisms for disposing of PFOA. In 1966, DuPont staffers suggested disposing of PFOA in steel drums so that it would not leak into the air or into drinking water.

33. Nevertheless, when DuPont opened the Fayetteville Works plant in 1971, it disposed of water containing PFOA and other PFCs in the Cape Fear River.

34. Throughout the 1970s, DuPont continued to collect evidence that PFOA could accumulate in the human body and cause a variety of illnesses. In 1978, a company called 3M—which manufactured PFOA for DuPont—told DuPont that PFOA had accumulated in the blood of 3M employees who had been exposed to the substance. DuPont then tested its own employees and found that they too had PFOA in their blood.

35. In 1978, DuPont began to review employee medical records and found that workers exposed to PFOA and similar chemicals at DuPont's New Jersey plant had increased rates of endocrine disorders. DuPont also found that workers exposed to PFOA more often had abnormal liver function tests more frequently. Nevertheless, DuPont did not disclose its findings to regulators.

36. In 1979, DuPont and 3M conducted additional tests and discovered that PFOA caused abnormal enzyme levels in dogs and fatal illnesses in monkeys.

37. Despite the growing body of evidence suggesting that PFOA was toxic, DuPont continued to dispose of PFOA in unsafe ways at the Fayetteville Works facility. In or around 1979, DuPont began disposing of PFOA-laden wastewater in unlined biosludge settlement lagoons. DuPont knew or should have known that wastewater poured into those lagoons would flow into the Cape Fear River.⁷

38. As DuPont's emissions of PFOA increased, so did the evidence that PFOA was dangerous. In 1981, DuPont learned that PFOA caused birth defects in rodents. As a result of this study, DuPont removed female workers from jobs that caused PFOA exposure at its Washington Works plant in West Virginia. But DuPont did not issue any sort of warning to women who lived near the Washington Works plant or the Fayetteville Works plant. Nor did DuPont report its concerns about PFOA to the EPA.

39. In 1988, DuPont researchers concluded that PFOA caused Leydig cell tumors in rodents. As a result, DuPont classified PFOA as a possible carcinogen (*i.e.*, a potential cancer-causing substance).

⁷ See Phase I Resource Conservation and Recovery Act ("RCRA") Facility Investigation ("RFI"), dated April 14, 2003 and revised August 1, 2003; Phase II RFI dated June 2006, and its August 2009 Addendum.

40. Given the emerging evidence that PFOA could cause health problems, 3M shipped PFOA to DuPont in 1988 with a notice stating that PFOA residue should be “mix[ed] with flammable material and incinerate[d] in an industrial or commercial facility.” But DuPont did not incinerate all of the PFOA it produced at the Fayetteville Works facility; instead, it continued to discharge substantial amounts into the Cape Fear River and the surrounding air.

41. In 1989, DuPont researchers completed a review of employee health records at DuPont’s Washington Works plant in West Virginia, which handled PFOA. The researchers found a significant excess of kidney and other urinary cancers among male employees.

42. While the newly discovered links between PFOA and cancers prompted DuPont to warn its employees about the potential hazards of the chemical, DuPont did not warn the community surrounding the Fayetteville Works plant or those drinking water from the Cape Fear River. Nor did DuPont stop discharging PFOA and other PFCs into the community’s drinking water and air.

43. In 1994, a DuPont committee drafted a “white paper” about PFOA. The paper discussed a study published in the *Journal of Occupational Medicine*, which found that workers exposed to PFOA were more likely to die of prostate cancer. In light of that study—as well as the other evidence that PFOA was toxic—the authors of the white paper considered strategies for “replac[ing] [PFOA] with other more environmentally safe materials.” Nevertheless, DuPont did not direct Fayetteville Works staff to stop discharging PFOA and similar chemicals into the Cape Fear River and surrounding air.

44. By 2000, 3M—which supplied most of DuPont’s PFOA—had seen enough evidence about the dangers of PFOA that it decided to stop manufacturing the substance. Instead of looking for PFOA alternatives, however, DuPont resolved to manufacture PFOA on its own.

45. But DuPont faced a problem: if it told regulators about the dangers of PFOA and its components, the regulators might not let DuPont produce it. So, DuPont decided to lie.

46. On May 3, 2001, DuPont asked the North Carolina DEQ to renew its NPDES Permit. The renewal application explained that DuPont intended to begin manufacturing APFO, the ammonium salt of PFOA, at Fayetteville Works. Then, the application made several false claims about the health effects of APFO, including: (i) a claim that there had been “no observed health effects in workers” in the forty years that DuPont had used the chemical; (ii) a claim that “epidemiological data from others in [the] industry supports its conclusion that APFO does not pose a health concern to humans or animals at levels present in the workplace or environment”; and (iii) a claim that the compound is “is neither a known developmental toxin nor a known human carcinogen.” Given all of the studies in its possession,⁸ DuPont knew or should have known that these statements were inaccurate.

47. In 2002, before its NPDES Permit renewal application had been approved, DuPont began producing APFO at the Fayetteville Works facility. The manufacturing continued for at least a decade.

48. In or around 2002, DuPont submitted supplemental information in support of its NPDES Permit renewal application to the North Carolina DEQ. In the supplement, DuPont stated that its PFOA manufacturing operation at Fayetteville Works would have no process wastewater discharges because the wastewater would be captured and incinerated off site. With that assurance from DuPont, the DEQ granted the NPDES renewal application in 2004. Crucially, the renewed permit did not authorize DuPont to discharge the PFOA manufacturing wastewater, which included GenX and other dangerous PFCs, into the river. Nor did the permit allow DuPont to

⁸ See CFPUA Notice.

discharge PFCs into the air. But DuPont did both.

49. On May 1, 2006, DuPont again submitted a NPDES Permit renewal application to the DEQ. The application represented that: (i) wastewater from PFOA manufacturing operations was “collected and shipped off-site for disposal”; (ii) “[n]o process wastewater from this manufacturing facility [was] discharged to the site’s biological [wastewater treatment plant] or to the Cape Fear River”; (iii) the PFOA produced at the facility was “used to produce fluoropolymers and fluorinated telomers, but none of the produced PFOA [was] used at the Fayetteville Works site”; (iv) DuPont manufactured five Nafion products, including FLPR Vinyl Ether monomers and HFPO monomers (hexafluoropropylene oxide); and (v) the Vinyl Ether and HFPO monomers were shipped to other DuPont locations to produce various fluorochemical products such as Teflon, while the Nafion wastewater was treated in the facility’s wastewater treatment plant. The DEQ issued the renewed NPDES Permit on May 25, 2007.

50. Government investigations later revealed that DuPont misrepresented the way it handled PFOA in its NPDES Permit applications. A Phase II Resource Conservation and Recovery Act (“RCRA”) Facility Investigation (“RFI”) dated June 2006, and its August 2009 Addendum found that there was PFOA contamination in soil and groundwater throughout Fayetteville Works. The investigations also noted chemical releases at the Nafion manufacturing area, including from solid waste management units (“SWMUs”) handling Nafion wastewater.

51. In 2011 and 2012, DuPont received the results of the first comprehensive study of the effects of PFOA on human health—called the “C8 Health Project” (because PFOA is sometimes known as C8)—which confirmed that PFOA causes cancer and a host of other health problems in humans. The C8 Health Project was created as part of the settlement agreement reached in *Jack W. Leach, et al. v. E.I. du Pont de Nemours & Company*, No. 01 Civ. 608 (W.Va., Wood County Circuit Court, April 10, 2002). That case—and 3,000 others like it—alleged that a

DuPont plant in Parkersburg, West Virginia spilled PFOA into the Ohio River, contaminating the drinking water of more than 60,000 people in West Virginia and Ohio. The C8 Health Project tracked health outcomes for those individuals, to determine the extent to which PFOA caused disease. The project was one of the largest toxicology/epidemiology studies ever conducted, with 69,030 study participants providing health data and blood samples for laboratory testing. Three world-renowned epidemiologists (the C8 Science Panel) analyzed 55 health outcomes for this group and concluded that PFOA was probably linked to six outcomes: kidney cancer, testicular cancer, ulcerative colitis, thyroid disease, hypercholesterolemia, and pregnancy-induced hypertension.

52. Similarly, in 2013, a study of humans exposed to PFOA suggested that PFOA exposure was linked to kidney cancer, testicular cancer, prostate cancer, ovarian cancer, and non-Hodgkin lymphoma.

53. Despite these sobering results, DuPont continued its reckless discharges of PFCs into the Cape Fear River, while providing false assurances to state regulators that it was processing PFCs in a responsible manner.

54. Between 2011 and 2013, the Fayetteville Works facility spilled PFOA on at least seven occasions, including once in June 2011 (at the PPA facility) and twice in March 2012 (at the Nafion facility and the Waste Fluorocarbon Storage Tank). Although DuPont had an obligation to report each of those spills—because its NPDES Permit did not authorize PFOA discharges⁹—DuPont reported none of them (until they were uncovered years later by a government investigation). As a result, state regulators were unable to take steps to warn families whose drinking water was contaminated by the PFOA spills.

⁹ 2014 RFI report; NPDES Permit No. NC0003573.

2. DuPont's History with GenX and other PFCS

55. Since the 1980s, Defendants have also been discharging GenX and other PFCs into the Cape Fear River and the surrounding air. Defendants repeatedly hid those discharges from state and federal regulators who could have protected North Carolina families from GenX and its dangerous chemical cousins.

56. In 1980, the Fayetteville Works plant began discharging wastewater from its vinyl ether manufacturing process—which contained significant amounts of GenX—into the Cape Fear River. Around the same time, the plant began discharging additional waste streams containing other PFCs.

57. DuPont then began to lie to government regulators about the way it was discharging dangerous wastewater. In or around December 1995, DuPont asked the North Carolina Department of Environment and Natural Resources (“DENR,” now the Department of Environmental Quality, “DEQ”) to renew DuPont’s NPDES Permit. DuPont’s renewal application included a request to reroute Nafion wastewater to bypass the facility’s wastewater treatment plant. DuPont falsely indicated in its permit application that the only significant pollutant in the “low biodegradable” wastewater was fluoride. However, the wastewater also included GenX and other PFCs.

58. In the early 2000s, when the EPA learned of the dangers associated with PFOA, DuPont knew that it would soon have to find a replacement product. DuPont eventually settled on GenX as the best available alternative to PFOA.

59. In 2009, DuPont and the EPA reached a consent order pursuant to the Toxic Substances Control Act (“Consent Order”), in which DuPont agreed to modify its Teflon manufacturing process, replacing PFOA with GenX. In negotiating this agreement, DuPont represented that GenX would probably be safer than PFOA because it would biodegrade and pass

through the human body more quickly, causing less damage. Despite this representation, the Consent Order stated that “EPA ha[d] concerns that [GenX] w[ould] persist in the environment, . . . bioaccumulate, and be toxic (‘PBT’) to people” In light of those concerns, the Consent Order instructed DuPont to study whether GenX was biodegradable and whether GenX caused illnesses in animals. The order further instructed DuPont to “recover and capture (destroy) or recycle [GenX] from all the process wastewater effluent streams and air emissions (point source and fugitive) at an overall efficiency of 99%” The Consent Order may have instructed DuPont to take even more precautions if DuPont had disclosed that it had already discharged GenX—as a waste product—into the Cape Fear River for 30 years. But DuPont kept that crucial fact secret. Alternatively, the Consent Order might have required more of DuPont if the company disclosed the fact that, as of 2009, it was *still* discharging substantial amounts of GenX into the Cape Fear River and surrounding air. But DuPont falsely claimed that it was “currently” sending GenX waste “to an off-site RCRA incinerator.”

60. When DuPont conducted the studies contemplated by the Consent Order, it learned that the EPA was right to be concerned about GenX. On March 15, 2010, DuPont submitted a study to the EPA, showing that GenX—like PFOA—was not biodegradable. Consistent with government guidelines,¹⁰ DuPont’s study measured the extent to which GenX biodegraded over 28 days. The study authors found that GenX did not biodegrade at all during the test period. More specifically, they found that:

[b]ased on the residue analysis, **the biodegradation of the test substance [i.e., GenX] was 0%** and there was hardly any change for the test substance in the ‘abiotic’ vessel during the testing period. The BOD results showed that **biodegradation of the test substance was both <1% after 14 and 28 days**. The test was valid because the level of biodegradation of [a control] substance aniline exceeded

¹⁰ See SEPA HJIT 153-2004, “the guidelines for the testing of chemicals,” OECD Procedure 302C, “Inherent Biodegradability: Modified MITI Test (II),” adopted May 1981.

40% after 7 days, and 65% after 14 days. **Therefore, the test substance was not inherently biodegradable under this test condition.**

61. In addition, the animal studies contemplated by the Consent Order demonstrated that rodents exposed to GenX—like rodents exposed to PFOA—suffered severe health consequences. In July 2010, DuPont submitted the results of two rodent studies to the EPA, showing that rodents exposed to GenX had birth defects, early birth and low birth weight, liver necrosis (*i.e.*, dead liver tissue), and cellular deformation indicative of liver disease and early-stage cancer.

62. More specifically, DuPont’s studies showed that, among rodents exposed to GenX:

There was a dose-related increase in the number of dams [female rodents] found with **early deliveries** on GD 21.

In addition, mean fetal weight was **8 and 28% lower** (statistically significant) than controls at 100 and 1000 mg/kg/day, respectively.

A higher mean litter proportion of 14th rudimentary ribs was observed in the 1000 mg/kg/day group, resulting in a higher mean litter proportion of **total skeletal variations and total developmental variations**

In addition, the study’s authors found “[f]ocal necrosis of the liver . . . in some females in the 100 and 1000 mg/kg/day groups in a dose-related manner.” Similarly, non-maternal rodents exposed to GenX had liver diseases, including focal necrosis and an increase of peroxisome proliferators (which have been shown to cause liver disease and induce tumors).

63. Despite the results of these studies, DuPont repeatedly violated the Consent Order’s instruction to “recover and capture (destroy) or recycle [GenX] from all the process wastewater effluent streams and air emissions (point source and fugitive) at an overall efficiency of 99%” Instead, DuPont discharged significant quantities of GenX into the Cape Fear River, the groundwater, and the air surrounding the Fayetteville Works plant. Those discharges flew in the

face of the Consent Order’s express statement that “uncontrolled . . . disposal of [GenX] may present an unreasonable risk of injury to human health and the environment.”

64. Recognizing that it was violating the Consent Order, DuPont continued to conceal its discharges of GenX into the Cape Fear River. In 2010—less than a month after DuPont sent the results of the rodent studies to the EPA—DuPont environmental manager Michael Johnson met with the DEQ’s Division of Water Quality (“DWQ,” subsequently Division of Water Resources (“DWR”)) as part of its NPDES Permit renewal process. A state regulator’s handwritten notes of the meeting suggested that Johnson promised to replace the PFOA at Fayetteville Works with a new material called “Gen-X (C-3 Dimer),” and further promised that the company would dispose of the new material “offsite by incinerator.” In fact, DuPont continued discharging GenX and other PFCs into the Cape Fear River without notifying the EPA, area residents, drinking water providers, or state and local officials.

65. On January 28, 2011, DuPont submitted the results of another rodent study to the EPA. Like the earlier studies, the new study found that rodents exposed to GenX developed liver necrosis and liver cell damage that could be a precursor to cancer. As the study’s authors put it:

Hepatocellular hypertrophy [among rodents exposed to GenX] was characterized by cytoplasmic eosinophilic stippling that is consistent with **peroxisome proliferation**. In the 5 mg/kg/day F0 males and females, other **liver lesions** included increases in single cell **necrosis**, **mitotic figures**, lipofuscin pigment, and **focal necrosis** (females only).

66. Despite these test results—and their marked similarity to the results of the PFOA animal studies—DuPont continued to discharge water contaminated with GenX into the Cape Fear River and to deceive state regulators about its wastewater treatment processes.

67. On April 29, 2011, DuPont submitted a new NPDES Permit renewal application. Like its earlier renewal applications, the 2011 application represented that: (i) “[a]ll process

wastewater generated from [the facility producing GenX] is collected and shipped off-site for disposal”; and (ii) “[n]o process wastewater from this manufacturing facility is discharged to the site’s biological [wastewater treatment plant] or to the Cape Fear River.” Once again, these statements were inaccurate. Relying on these false statements, the DEQ approved the renewal application on February 6, 2012.

68. Meanwhile, DuPont repeatedly tried to disprove the results of the rodent studies it was required to submit to the EPA. But each rodent study only confirmed that GenX was toxic to animals. Unable to obtain the results it wanted, DuPont asserted—without justification—that the rodent studies were irrelevant to the question whether GenX could harm humans.

69. In 2013, DuPont completed studies showing that rodents exposed to GenX had a higher incidence of liver tumors, pancreatic tumors, and testicular tumors. The rodents exposed to GenX also had a higher incidence of uterine polyps, though the study authors did not find the incidence of polyps to be statistically significant. In scientific terms:

Test substance-related **neoplastic changes** were observed at the high dose (500 mg/kg/day in females; 50 mg/kg/day in males) and included **hepatocellular tumors** in females and, in males, equivocal **increases in pancreatic acinar cell tumors and testicular interstitial cell tumors**.

70. Despite the fact that the 2013 rodent study followed standard scientific protocols—and was very similar to the rodent studies that DuPont had previously used to establish PFOA’s toxicity to humans—DuPont insisted that the results were not relevant to human health:

Based on the high dose threshold for these tumor responses in this study, the lack of genotoxicity of the test material across a battery of in vitro and in vivo tests, and the known responses of the rat versus other species, including humans, to these PPAR(a) associated tumor responses, these tumor findings are not considered relevant for human risk assessment.

71. In 2014, DuPont scientists dismissed the results of yet another, more extensive evaluation of the toxic effects of GenX, “Evaluation of chronic toxicity and carcinogenicity of ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate in Sprague–Dawley rats” (“GenX Report”). The study—conducted by DuPont scientists—again showed that GenX caused serious health problems in rodents, including “[i]ncreases in enzymes indicative of liver injury,” and tumor cells—some of them cancerous—in the liver, kidneys, stomach, tongue, pancreas, and testes.

72. Putting that point in more scientific terms, the GenX Report stated that, “[at] the interim necropsy, **non-neoplastic** test substance-associated effects were present in the liver of males at 50 mg/kg and in the liver and kidneys of females at 500 mg/kg.”

73. In addition:

Kidney changes in females at 500 mg/kg included tubular dilation, edema of the renal papilla, **transitional cell hyperplasia in the renal pelvis**, tubular mineralization, **renal papillary necrosis** and CPN. Tubular dilation frequently occurred in an ascending pattern extending from the papilla to the outer cortex, while at other times it was present only in the papilla. **Edema of the papilla** was characterized by increased rarefaction or myxomatous change in the papillary interstitium, sometimes with polypoid protrusions from the lateral surface of the papilla. The **edema** and tubular dilation were often associated with hyperplasia of the transitional cell epithelium lining the papilla and pelvis. Small foci of tubular mineralization were often present and, in some animals, necrosis of the tip of the papilla was present.

74. Moreover, in female rodents given 500 mg/kg, [there were] statistically significant increases in **hyperplasia** of squamous epithelium were observed in the nonglandular stomach (limiting ridge only) and tongue (in association with subacute/chronic inflammation in the tongue). Hyperplasia is the enlargement of an organ or tissue caused by an increase in the reproduction rate of its cells, often as an initial stage in the development of cancer.

75. The GenX Report ultimately concluded that the rodents suffered from tumors called carcinomas and adenomas:

Compound-related neoplastic changes occurred in the livers of females administered 500 mg/kg and included **increased incidences of hepatocellular adenoma and carcinoma**. These tumors occurred in association with the degenerative and necrotic liver lesions observed at this dose as described above. Hepatocellular tumors and test substance-associated degenerative and necrotic lesions were not observed in females at lower doses and **the incidences of hepatocellular tumors were similar in all male groups**. . . .

In males administered 50 mg/kg, **a statistically significant increase in the combined incidence of pancreatic acinar cell adenomas and carcinomas was seen**, but neither the incidence of adenoma or carcinoma alone was statistically increased, although the incidence of carcinomas (2.9%) was slightly outside the historical range of 0–1.7%.


. . .

The incidence of **Leydig cell adenomas** (11.4%) was increased above historical control ranges for this tumor (0–8.3%) in males administered 50 mg/kg, although this increase was not statically significant compared to controls. In addition, a Leydig cell adenoma was present in 1 male at the interim necropsy in the 50 mg/kg group. The incidence of Leydig cell hyperplasia was also increased above historical control range in this group at terminal sacrifice (also 0–8.3%; although again, this incidence was not statistically significant versus controls. However, comparison to within-study controls was complicated by the fact that controls had a relatively high incidence of Leydig cell hyperplasia (10%). Based on the above considerations and the known activity of PPAR α agonists to produce Leydig cell hyperplasia and adenomas in rats, the relationship to the test compound for **these lesions was considered equivocal in this study**.

76. These results should have caused DuPont to classify GenX as a potential carcinogen. As a public health expert recently testified against DuPont in another case, “The only time that you can discount . . . tumor-causing effects, in animals, is if you know the mechanism by which [a] substance is causing cancer [in the animals] and you know that mechanism is not relevant to humans.” The DuPont scientists who conducted the GenX Report specifically acknowledged that they did not have “definitive” data on all of the mechanisms by which GenX caused tumors. Yet DuPont dismissed the results as likely irrelevant to humans.

77. DuPont offered very feeble reasons for discounting the results of the GenX report, suggesting that it was looking for any possible excuse to justify its decision to discharge GenX into the Cape Fear River. For example, DuPont claimed that the high doses of GenX given to the rodents were not representative of human exposures to GenX. But all two-year cancer rodent studies follow the protocol developed by the U.S. National Toxicology Program, which requires that rodents receive an elevated dose of a potential toxin.

78. The DuPont scientists who authored the GenX Report also turned a blind eye to the well-known fact that, in light of its molecular structure, GenX likely disrupts cellular functions. GenX has a chemical carboxyl group which likely bonds with cells and impairs normal growth and function, which could cause the cancer and other diseases that the scientists observed in the rodents.



79. Finally, the authors of the GenX Report ignored the fact that rodent studies predicted that PFOA—which is chemically similar to GenX—was toxic to humans, and that prediction was borne out by the C8 health study. The authors of the GenX report therefore had reason to believe that rodents could be used to gauge the toxicity of PFCs to humans.

80. Later studies conducted by independent researchers show just how hard DuPont scientists must have worked to dismiss the results of their rodent studies. For example, in January 2018, Stockholm University published the results of a rodent study suggesting that GenX is even more toxic than PFOA.¹¹

81. As surely as DuPont continued to ignore the results of scientific studies showing that GenX was dangerous, it continued lying to state regulators. On June 24, 2015, Michael Johnson, now Chemours' environmental manager, met with DWQ regulators to discuss the identification of a new perfluorinated compound in the Cape Fear River. According to handwritten notes by a state regulator, Johnson stated that a PFOA replacement equivalent to "C3 Dimer Acid/Salt" or "HFPO Dimer Acid Ammonium Salt," was "no longer discharged to river." Both of those compound names are technical references to GenX. But DuPont was still discharging GenX into the Cape Fear River in 2015.

82. Chemours submitted its most recent NPDES Permit renewal application on April 27, 2016. The application contained the same misrepresentations as DuPont's April 2011 renewal application.

83. The motive for DuPont's decades-long scheme to deceive regulators about its PFC discharges was simple: DuPont wanted to avoid the cost of dealing with PFCs safely. As DuPont's counsel noted following the revelation that DuPont had discharged PFOAs into West Virginia's water supply: "We really should not let situations like this arise. . . . [T]he plant trie[d] to save money and apparently did not consider how it might look"

¹¹ Gomis, et al, Env. Intern. 113 (2018) at 1 ("The toxicity ranking using modeled serum (GenX > PFOA > PFHxA > PFBA) and liver (GenX > PFOA≈PFHxA≈PFBA) concentrations indicated that some fluorinated alternatives have similar or higher toxic potency than their predecessors when correcting for differences in toxicokinetics.")


D. Defendants' Toxic Discharges to the Cape Fear River and Air Emissions Come to Light

84. A few years ago, North Carolina State University Professor Detlef Knappe took samples from the Cape Fear River to get a better understanding of how PFCs may have affected Wilmington's water supply. Greatly alarmed by his analysis of the samples, he contacted the Cape Fear Public Utility Authority ("CFPUA")—the public authority responsible for providing water to Wilmington residents. On May 3, 2016, Professor Knappe informed the CFPUA that, according to his findings, GenX and related contaminants were detected at an average concentration of 631 ppt at the CFPUA intake.

85. On November 10, 2016, Dr. Knappe, together with co-authors at the University of North Carolina at Charlotte and several government agencies, published a paper showing elevated levels of GenX and numerous other PFCs in a drinking water treatment plant along the Cape Fear River near Wilmington. The authors expressed particular concern about GenX, which "presents a greater drinking water challenge" than the older industrial compounds it was meant to replace because it is harder to remove from the water.

86. On November 23, 2016, Dr. Knappe shared his published research by email with a number of city and county water treatment plants and government officials in the DEQ, including current DWR Director Jay Zimmerman and then-Assistant Secretary of the Environment Tom Reeder. Knappe noted that levels of GenX "were very high in Wilmington" and that none of the newly discovered compounds being discharged by the Chemours plant were being removed by the city's Sweeney treatment plant. The study abstract noted a number of other troubling features of the PFCs in Wilmington's water:

ABSTRACT: Long-chain per- and polyfluoroalkyl substances (PFASs) are being replaced by short-chain PFASs and fluorinated alternatives. For ten legacy PFASs and seven recently discovered perfluoroalkyl ether carboxylic acids (PFECAs), we report (1) their occurrence in the Cape Fear River (CFR) watershed, (2) their fate in water treatment processes, and (3) their adsorbability on powdered activated carbon (PAC). In the headwater region of the CFR basin, PFECAs were not detected in raw water of a drinking water treatment plant (DWTP), but concentrations of legacy PFASs were high. The U.S. Environmental Protection Agency's lifetime health advisory level (70 ng/L) for perfluorooctane-sulfonic acid and perfluorooctanoic acid (PFOA) was exceeded on 57 of 127 sampling days. In raw water of a DWTP downstream of a PFAS manufacturer, the mean concentration of perfluoro-2-propoxypropanoic acid (PFPrOPrA), a replacement for PFOA, was 631 ng/L ($n = 37$). Six other PFECAs were detected, with three exhibiting chromatographic peak areas up to 15 times that of PFPrOPrA. At this DWTP, PFECA removal by coagulation, ozonation, biofiltration, and disinfection was negligible. The adsorbability of PFASs on PAC increased with increasing chain length. Replacing one CF_2 group with an ether oxygen decreased the affinity of PFASs for PAC, while replacing additional CF_2 groups did not lead to further affinity changes.



87. The study identified 17 different PFCs in the water supply:

Table S1. Perfluoroalkyl substances (PFASs) detected in the Cape Fear River (CFR) watershed

Compound	Molecular weight	Formula	CAS #	# of perfluorinated carbons	Chain length (including all C, O and S)
Perfluorocarboxylic acids (PFCAs)					
Perfluorobutanoic acid (PFBA)	214.0	$\text{C}_4\text{HF}_7\text{O}_2$	375-22-4	3	4
Perfluoropentanoic acid (PFPeA)	264.0	$\text{C}_5\text{HF}_9\text{O}_2$	2706-90-3	4	5
Perfluorohexanoic acid (PFHxA)	314.1	$\text{C}_6\text{HF}_{11}\text{O}_2$	307-24-4	5	6
Perfluoroheptanoic acid (PFHpA)	364.1	$\text{C}_7\text{HF}_{13}\text{O}_2$	375-85-9	6	7
Perfluorooctanoic acid (PFOA)	414.1	$\text{C}_8\text{HF}_{15}\text{O}_2$	335-67-1	7	8
Perfluorononanoic acid (PFNA)	464.1	$\text{C}_9\text{HF}_{17}\text{O}_2$	375-95-1	8	9
Perfluorodecanoic acid (PFDA)	514.1	$\text{C}_{10}\text{HF}_{19}\text{O}_2$	335-76-2	9	10
Perfluorosulfonic acids (PFSA)					
Perfluorobutane sulfonic acid (PFBS)	300.1	$\text{C}_4\text{HF}_9\text{SO}_3$	375-73-5	4	5
Perfluorohexane sulfonic acid (PFHxS)	400.1	$\text{C}_6\text{HF}_{13}\text{SO}_3$	355-46-4	6	7
Perfluorooctane sulfonic acid (PFOS)	500.1	$\text{C}_8\text{HF}_{17}\text{SO}_3$	1763-23-1	8	9
Perfluoroalkyl ether carboxylic acids with one ether group (mono-ether PFECAs)					
Perfluoro-2-methoxyacetic acid (PFMOAA)	180.0	$\text{C}_3\text{HF}_5\text{O}_3$	674-13-5	2	4
Perfluoro-3-methoxypropanoic acid (PFMOPrA)	230.0	$\text{C}_4\text{HF}_7\text{O}_3$	377-73-1	3	5
Perfluoro-4-methoxybutanoic acid (PFMOBA)	280.0	$\text{C}_5\text{HF}_9\text{O}_3$	863090-89-5	4	6
Perfluoro-2-propoxypropanoic acid (PFPrOPrA)	330.1	$\text{C}_6\text{HF}_{11}\text{O}_3$	13252-13-6	5	7
Perfluoroalkyl ether carboxylic acids with multiple ether group (multi-ether PFECAs)					
Perfluoro(3,5-dioxahexanoic) acid (PFO2HxA)	246.0	$\text{C}_4\text{HF}_7\text{O}_4$	39492-88-1	3	6
Perfluoro(3,5,7-trioxaoctanoic) acid (PFO3OA)	312.0	$\text{C}_5\text{HF}_9\text{O}_5$	39492-89-2	4	8
Perfluoro(3,5,7,9-tetraoxadecanoic) acid (PFO4DA)	378.1	$\text{C}_6\text{HF}_{11}\text{O}_6$	39492-90-5	5	10

Page 3 of 12

88. The Wilmington *Star News* obtained a copy of Dr. Knappe's results, and on June 7, 2017, the paper broke the story that GenX, a chemical "linked to cancer and a host of other ailments has been found in the drinking water system of the Cape Fear Public Utility Authority (CFPUA), which cannot filter it."

89. That same day, the executive committee of CFPUA approved a letter to DEQ asking for help evaluating GenX.

90. Bowing to media scrutiny, Chemours met with DEQ officials on June 12, 2017, and informed them that for several decades, Fayetteville Works routinely discharged GenX and other PFCs into the Cape Fear River.

91. Two days later, DEQ and the North Carolina Department of Health and Human Services (“DHHS”) began an investigation into GenX in the Cape Fear River.

92. Shortly after the investigation began, the State of North Carolina set a preliminary health-based standard for GenX: drinking water should not contain more than 140 ppt of GenX. Notably, however, the preliminary standard does not take into account GenX’s cancer-causing potential. As the state put it, “Although the preliminary [standard is] based upon a study with combined cancer and non-cancer endpoints, the [140 ppt] goal considers non-cancer endpoints only.” Nor does the preliminary standard represent an appropriate safety level for vulnerable populations, such as children and individuals who have been exposed to other PFCs (such as the 16 other PFCs, at a minimum, that DuPont released into the Cape Fear River). If cancer risks, child safety, and other PFCs were taken into account, the standard would be considerably lower than 140 ppt.

93. On June 15, 2017, local officials held a closed meeting with Chemours staff. According to a *Star News* reporter’s notes from the meeting, the officials pressed Chemours’ plant manager on the amount of GenX that was likely discharged into the river. The Chemours plant manager attempted to evade questions but ultimately implied that literally tons of GenX had been discharged into the Cape Fear River over the past four decades.

94. In the same meeting, however, Kathy O’Keefe, Chemours’ toxicologist, claimed that the massive discharges of PFCs were safe:

“I was surprised there was such a strong reaction but I understand it because it’s an emotional issue. I’m a mother. I have two children. I have tons to worry about with my children. I don’t want to worry about what’s in their water, what’s in their food.”

“I think a lot of it is the unknown. There’s this toxic chemical in our water. There’s the first rule of toxicology which is the dose makes the poison. Just because something is present doesn’t mean it’s going to cause harm.”

“When you cook Brussels sprouts, did you know you release formaldehyde?”

“The easiest thing to do is say these are the levels that we see, this is the safe level that has been established and I always use the term margin of safety but there’s probably a better term to use. There’s a safe distance between the (level) seen in the water and the level of safety that’s been set by our agencies.”

95. Tests performed just four days later proved Chemours’ toxicologist wrong: on June 19, 2017, DEQ regulators in Fayetteville and Wilmington began sampling and testing 13 locations along the Cape Fear River for the presence of GenX; their results showed that finished water from four water treatment plants had GenX concentrations exceeding the state’s safety standard of 140 ppt, including a) Bladen Bluffs (790 ppt); b) NW Brunswick (910 and 695 ppt); c) Pender County (421 ppt); and d) CFPU Sweeney (1100 and 726 ppt).

Gen X Concentration in Finished Water						
Location	06/22/2017 results ppt		06/29/2017 results ppt		07/06/2017 results ppt	
	Test America, CO	EPA RTP, NC	Test America, CO	EPA RTP, NC	Test America	EPA RTP, NC
International Paper Finished	690	523	140	111	N/A	80
NW Brunswick Water Treatment Plant (WTP) Finished	910	695	51	52	N/A	125
Pender Co. 421 WTP Finished	340	269	160	112	N/A	68
CFPUA Sweeney Finished	1100	726	110	100	N/A	87

Gen X Concentration in Finished Water		
Location	06/19/2017 results ppt	06/26/2017 results ppt
	Test America, CO	Test America, CO
Bladen Bluffs Finished	790	76

96. On June 20, 2017, under extreme public pressure, Chemours announced it would “capture, remove and safely dispose of” wastewater containing GenX, instead of discharging it into the Cape Fear River. Chemours did not mention that it had already contaminated the groundwater, and was still emitting GenX into the air.

97. On July 10, 2017, DEQ received the first responses from the Colorado lab that tested the water samples drawn in June and July 2017. The lab found raw water concentrations of GenX as high as 39,000 ppt, and water treated by CFPWA with concentrations of 790 ppt—far greater than the preliminary safety threshold of 140 ppt.

98. On August 31, 2017, the EPA revealed that it had discovered two other chemicals in the Cape Fear River that are wastes of the Nafion production process, which it referred to as Nafion byproduct 1 and Nafion byproduct 2. Both chemicals have longer carbon chains than GenX, with each compound comprising a chain of seven fluorinated carbon atoms. The concentrations of these Nafion byproducts are as follows:

Date	Nafion Byproduct 1 (ppt)	Nafion Byproduct 2 (ppt)
Week 1	53	1640
Week 2	143	4320
Week 3	N/A	N/A
Week 4	120	2360
Week 5	158	7860
Week 6	72	4670

These concentrations are as high as 60 times greater than the EPA’s health-based standard of 70 ppt for the Nafion byproducts’ close chemical cousin, PFOA.

99. Around the same time, DWR collected and tested groundwater samples from 14 groundwater-monitoring wells on Chemours’ property. DWR detected high concentrations of

GenX in 13 wells. Of the 13 wells, six showed GenX concentrations over 150 times the state's drinking water health goal; three had levels exceeding 80 times that goal; and one exceeded 437 times the goal. DWR also detected PFOS and PFOA in four wells; in two of them, the combined concentration of PFOA and PFOS exceeded 3,000 ppt. Perhaps most alarmingly, one of the contaminated wells was located uphill from the plant. Because water does not flow uphill, that suggests that some GenX had traveled through the air and settled over nearby property.

100. On September 5, 2017, DWR filed a Notice of Intent to Suspend Chemours' NPDES Permit within 60 days because Chemours "misrepresentat[ed] [and] failure[d] to disclose fully all relevant facts." DWR also explained that it:

found no evidence in the permit indicating that Chemours or DuPont (Chemours's predecessor) disclosed the discharge to surface water of GenX compounds at the Fayetteville Works. In particular, the NPDES permit renewal applications submitted to DWR contained no reference to "GenX" or to any chemical name, formula, or CAS number that would identify any GenX compounds in the discharge. In fact, the information provided by DuPont and Chemours led DWR staff to reasonably believe that no discharge of GenX had occurred.

101. On September 7, 2017, the State of North Carolina, by and through Michael S. Regan, Secretary of the North Carolina Department of Environmental Quality, filed a Complaint and motion for a temporary restraining order against Defendant the Chemours Company in Bladen County Superior Court, No. 17 CVS 580, seeking certain relief from Chemours based on Chemours and its predecessor's (DuPont's) violations of various water-quality laws and regulations on account of its unlawful discharges of GenX and other PFCs.

102. The next day, on September 8, 2017, Chemours attempted to signal to the public that it would voluntarily comply with DEQ by signing the partial consent order. It represented that it would continue its efforts to prevent GenX discharges and would do the same for Nafion byproducts 1 and 2. On the same day that it signed the partial consent order, however, counsel for

Chemours sent DEQ a private letter in which it claimed that DEQ's "zero discharge" limitation was arbitrary and capricious, procedurally defective, contrary to statute, and unconstitutional.

103. That same month, Chemours and DEQ both began testing privately owned wells within a 1-mile radius of Fayetteville Works for GenX. By the end of September, DEQ had ordered Chemours to supply bottled drinking water to more than 20 private well owners whose wells contained GenX concentrations exceeding the state's drinking water health goal of 140 ppt. By the end of 2017, the number of wells with GenX concentrations exceeding the state health goal would climb to 115, with another 140 wells testing positive for GenX but falling below the state health threshold.

104. On November 3, 2017, DEQ conducted an on-site inspection of the Fayetteville Works facility. During the inspection, and only upon questioning by DEQ staff, Chemours' employees admitted that, not but one month earlier, on October 6, 2017, Chemours' vinyl-ethers production facility had leaked onto the ground an unknown quantity of C3 dimer-acid fluoride—a chemical compound that, when mixed with water, can break down into a chemical equivalent of GenX. Over the course of the next three days, rain events caused the chemical to be absorbed into storm water and discharged directly into the Cape Fear River via Chemours' outfall 002. Chemours failed to bring the spill to DEQ's attention, despite the fact that Chemours' NPDES Permit required it to report any significant or abnormal discharge to DEQ within 24 hours.

105. On November 16, 2017, and partly due to Chemours' failure to report the significant pollution incident on October 6, 2017, DEQ moved to partially suspend Chemours' NPDES Permit. The partial revocation would bar Chemours from discharging into the Cape Fear River any process wastewater containing GenX, Nafion byproducts, or any other PFAS.

106. One day later, on November 17, 2017, DEQ announced an investigation into reports from Chemours of yet another leak from the Fayetteville Works vinyl-ethers production facility—

this time by air. Chemours informed DEQ that a rupture in the manufacturing area's condensation tower had allowed 55 pounds of hexafluoropropylene oxide (HFPO) and 70 pounds of HFPO dimer acid fluoride to be released into the air.

107. In early December 2017, two events raised additional concerns that PFCs including GenX were spreading by air. First, in early December, GenX in a concentration of 2,070 ppt was detected in the honey of a farmer several miles south of Fayetteville Works. Second, DEQ found concentrations of GenX greater than three times the state's 140-ppt health goal in five wells located on the eastern bank of the Cape Fear River—that is, across the river from Fayetteville Works. In a December 2017 public hearing, DEQ indicated that, in addition to Defendants' contamination of the Cape Fear watershed, Defendants had also caused the contamination of the surrounding airshed. DEQ estimated that, between 2012 and 2016, air emissions from the Fayetteville Works plant had GenX depositions exceeding 3,000 micrograms per square meter in land located close to the plant—including parcels located east of the Cape Fear River. It also estimated that parcels located over three miles northeast of the plant could contain depositions of over 500 micrograms per square meter.

108. Very recent testing suggests that GenX and other PFCs may have contaminated plants and vegetables around the Fayetteville Works plant. On a video call between Dutch scientists (who are studying GenX contamination at Chemours' plant in Dordrecht, Netherlands) and North Carolina's science advisory board, the Dutch scientists noted that carrots, beets, lettuce and other vegetables at 10 sites around the Chemours plant had been tested for PFCs. Approximately 40% were contaminated with GenX and/or PFOA. Thus, North Carolina residents may have been eating—as well as drinking—PFCs.

109. In November 2018, the North Carolina State University Center for Human Health and the Environment released preliminary results from a study of blood and urine samples taken

from individuals living nearby the Fayetteville Works plant who consumed water from private wells and from individuals living in New Hanover County. The authors reported that four newly-identified PFCs—as well as older PFCs such as PFOA—were detectable as present in the study participants’ blood. They further reported that 99% of the participants’ blood tested positive for Nafion byproduct 2 at a median concentration of nearly 3 parts per billion (ppb). The study also confirmed that individuals who live near Fayetteville Works have more PFCs in their blood than individuals who live in other places (*e.g.*, individuals in Raleigh, Durham, and Chapel Hill, North Carolina, as well as Dayton, Ohio).¹²

110. On February 25, 2019, Chemours and the State of North Carolina (through the DEQ) signed, and the Bladen County Superior Court entered a Consent Order that, among other things, ordered Chemours to provide remedial measures to certain parties affected by Defendants’ wrongful discharge of PFCs, including households, businesses, schools, and public buildings that use drinking-water wells. Specifically, the Consent Order requires Defendant Chemours to provide public water supplies, or under certain circumstances, whole-building filtration systems (and maintenance) to those parties whose drinking-water wells are contaminated by GenX and other PFCs in a total amount exceeding 140 ppt or any applicable health advisory standard (currently set at 140 ppt), whichever is lower. Such parties may alternatively opt to receive reverse osmosis systems for every drinking water sink in their building. The Consent Order also requires Chemours to provide a minimum of three under-sink reverse osmosis water-filtration systems (or equivalent treatment) to any party with a drinking-water well contaminated by GenX (or any other PFC specifically listed on an attachment to the Consent Order) if the well-water tests above 10 ppt for

¹² NC State University Center for Human Health and the Environment, *GenX Exposure Study* (2018). Available at: <https://chhe.research.ncsu.edu/the-genx-exposure-study/> (last accessed Aug. 20, 2019).

any given compound or exceeds 70 ppt for the total concentration of all listed compounds. For any resident who receives permanent water supplies as a result of the Consent Order, Chemours must also pay for any and all water bills for each affected party for 20 years up to \$75 per month, subject to adjustment by DEQ every 2 years for certain criteria specified in the Consent Order. Chemours is also required to provide ongoing testing of water for certain residents, as well as bottled water until the remedial measures provided for in the Consent Order are executed or a party declines the remedial measures provided therein.

E. Remediation of Buildup of GenX, Nafion Wastes, and Related Contaminants in Residential Plumbing Requires Plumbing and Fixture Replacement

1. PFCs, Including GenX and Nafion, Bond With Biofilms, Scale, Iron, and Rust in Pipes, Fittings, Fixtures and Appliances.

111. For a variety of reasons, Gen X and other PFCs will be very difficult to remove from North Carolina residents' pipes, fittings, and fixtures.

112. First, scientific studies have consistently demonstrated that PFCs such as GenX and Nafion wastes bond with cells, including cells in the thin layer of microorganisms that coats municipal and residential pipes, water heaters, fixtures, and appliances, sometimes called a "biofilm." These biofilms can be difficult—if not impossible—to remove. But removing them is essential: individual microbes in a biofilm routinely die and break off from the film. The continuous dying and detachment of cells releases PFCs, including PFOAs, GenX and Nafion wastes, back into the water supply.

113. In addition to bonding with biofilm, PFCs, PFOAs and PFOS such as GenX and Nafion wastes can adsorp (*i.e.*, chemically bond) directly with the iron and iron oxide in pipes. The PFCs can then desorp back into the water supply.

114. PFCs, GenX and the C7 Nafion byproducts also exist in small stagnant pockets of water trapped in scale throughout homes' plumbing systems. If these small pockets of water are ever disturbed, they can release PFCs back into drinking water.

115. PFCs thus reside in bacteria, biofilm, scale, iron, and iron oxide in the bottom of water heaters, the nooks and crannies of rusted pipes, and valves, elbows, and water fixtures, among other locations. The pipes and fixtures thus act as a reservoir or sponge, continuously attracting and discharging GenX and other PFCs back into the water supply.

2. Remediation Can Only Be Accomplished By Replacing Pipes, Fittings, Appliances, and Fixtures and Installing Filtration Systems

116. Currently, there is no known means to filter GenX and certain other legacy PFCs out of the water supply on a large-scale, long-term basis. And even if drinking water utilities develop a filtering method, GenX and other PFCs are already bound to the bio-films in municipal pipes and residential pipes, fittings, fixtures, and appliances. The only solution is to: (i) install a sophisticated water filtration system at the juncture connecting municipal pipes to the pipes for individual homes and businesses; (ii) remove and replace plumbing, fixtures, fittings, and appliances inside individual homes and businesses; and (iii) provide bottled water to residents in the interim.

117. Meanwhile, until these remedial actions are complete, the residents will need to be supplied with bottled water for daily use. Many residents have already purchased bottled water for themselves to ensure the health and safety of their families.

F. Plaintiffs' Experiences

1. Victoria Carey

118. Victoria Carey lives in Leland, North Carolina, with her husband. Brunswick Regional Water & Sewer H2GO provides them with tap water from the Cape Fear River.

119. Since 2002, the Carey family, unaware of the nature and extent of the toxicity of the water contaminated by Defendants, regularly used the water for drinking, cooking, cleaning, bathing, and clothes washing.

120. After learning in the press of Defendants' contamination of the water supply, Ms. Carey had her home, including the hot water heater, tested. The testing revealed concentrations of GenX in excess of North Carolina's 140 ppt standard for GenX. As a result, Ms. Carey believes that these contaminants have now adhered to the plumbing in her home, diminishing her property value, and requiring abatement.

121. In addition, Ms. Carey has been diagnosed with thyroid nodules, a goiter (enlargement of the thyroid gland), and hyperthyroidism. Her husband has been diagnosed with a similar thyroid condition. Ms. Carey has also been diagnosed with an idiopathic immune condition. These illnesses are typical of those which DuPont concluded in its own studies are caused by GenX and other PFCs.

122. As a proximate result of Defendants' deliberately indifferent, intentional, reckless, and negligent actions, as set forth herein, Ms. Carey has experienced physical and emotional injury as well as injury to property.

2. Marie Burris

123. Dr. Marie Burris owns property at 21158 NC Highway 87 W, Fayetteville, North Carolina 28306, a few miles from the Fayetteville Works site. She resided there for 11 years until 2015, and currently rents the property out.

124. In October 2017, Ms. Burris was informed by the DEQ that "the concentration of GenX in your well water is greater than the N.C. Department of Health and Human Services (DHHS) drinking water goal of 140 ng/l for GenX." The test results were 322 ng/L.

125. DEQ recommended that she not use her water for drinking. Her tenant presently must rely on bottled water for drinking supplied by Defendant Chemours. Dr. Burris is concerned that unless a permanent solution is created, the value of her property will diminish.

3. Michael Kiser

126. Michael Kiser has lived in or around Wilmington since 1993. His source of water was the CFPUA at all of his locations. In 2011, he was diagnosed with colon cancer. In 2015, he was diagnosed with stomach cancer. He also suffers from ulcers and cysts on his liver and intestines. These illnesses are typical of those which DuPont concluded in its own studies are caused by GenX and other PFCs. His afflictions have resulted in surgery, hospitalization, loss of income, and a reduction in quality of life.

4. Brent Nix

127. Brent Nix owns residential property at 5008 Laurenbridge Lane, Wilmington, North Carolina 28409. He has occupied and resided at that property since December 2016. Mr. Nix previously occupied and resided at 4508 Alder Ridge Road, Wilmington, North Carolina for approximately five years before living at 5008 Laurenbridge Lane. Mr. Nix has consumed household water supplied by the Cape Fear Public Utility Authority (“CFPUA”) through water from the Cape Fear River during the length of his residencies at each of these addresses.

128. Mr. Nix is a triathlete who consumes a great deal of water. Shortly after the news broke of the drinking-water contamination caused by Defendants’ unlawful discharges, Mr. Nix stopped drinking water supplied by the public utility and switched to consuming bottled water only. The additional purchases of bottled water exceed \$100 per month.

129. In the fall of 2017, Mr. Nix was diagnosed with ulcerative colitis and diverticulitis.

130. As a result of Defendants’ conduct, Mr. Nix has suffered physical and property injury distinct from the general public and has not been able to enjoy the full use of his property,

specifically, the ability to drink his water. He has also had to purchase bottled water.

V. CLASS ALLEGATIONS

131. Plaintiffs' class includes both class claims and additional class-wide issues. Pursuant to Fed. R. Civ. P. 23(b)(2), 23(b)(3) and 23(c)(4), Plaintiffs request certification of a proposed class (the "Class") defined as: All persons who from February 1, 2015 to the present lived within New Hanover, Brunswick, Bladen, Cumberland, or Pender Counties, or who currently own property or businesses there.

A. Class Claims

132. On behalf of the Class, Plaintiffs will bring the following common claims: (i) negligence (causing property damage); (ii) gross negligence (causing property damage); (iii) negligence *per se* (causing property damage)¹³; (iv) public and private nuisance (causing property damage); (v) trespass (causing property damage and violations of Plaintiffs' bodily integrity); and (vi) unjust enrichment.

133. The number of Class members is sufficiently numerous to make class action status the most practical method for Plaintiffs to secure redress for injuries sustained and to obtain class-wide equitable injunctive relief.

134. There are questions of law and fact raised by Plaintiffs' claims common to those raised by the Class they seek to represent. Such common questions predominate over questions affecting only individual members of the Class.

135. The violations of law and resulting harms alleged by Plaintiffs are typical of the legal violations and harms suffered by the different Class members.

¹³ On April 19, 2019, the Court dismissed Plaintiffs' claims for negligence *per se*, public nuisance, and unjust enrichment. By including those claims in their Second Amended Complaint, Plaintiffs are *not* asking the Court to reconsider its April 19 decision; Plaintiffs only seek to preserve their appellate rights with respect to all claims.

136. As class representatives, Plaintiffs will fairly and adequately protect the interests of the Class members. Plaintiffs' counsel are unaware of any conflicts of interest between the class representatives and absent Class members with respect to the matters at issue in this litigation; the class representatives will vigorously prosecute the suit on behalf of the Class; and the class representatives are represented by experienced counsel. Plaintiffs are represented by attorneys with substantial experience and expertise in complex and class action litigation involving personal and property damage.

137. Plaintiffs' attorneys have identified and thoroughly investigated all claims in this action and have committed sufficient resources to represent the Class.

138. The maintenance of the action as a class action will be superior to other available methods of adjudication and will promote the convenient administration of justice. Moreover, the prosecution of separate actions by individual members of the Class could result in inconsistent or varying adjudications with respect to individual members of the Class and/or one or more of the Defendants.

139. Defendants have acted or failed to act on grounds generally applicable to Class members, necessitating declaratory and injunctive relief for the Class.

B. Additional Class-Wide Issues

140. In addition to the Class claims set forth above, Plaintiffs will also seek class certification as to particular class-wide issues, as permitted under Fed. R. Civ. P. 23(c)(4). These class-wide issues are common to members of the Class who may have sustained personal injury—in addition to property damage and violations of bodily integrity—as a result of Defendants' negligence, gross negligence, negligence *per se*, nuisance, or trespass. Once these class-wide issues are resolved, Class members may pursue their personal injury claims on an individual basis.

141. The additional class-wide issues include the issues of whether and how: (i) Defendants' negligent conduct was capable of damaging Class members' health (beyond contaminating their bodies); (ii) Defendants' grossly negligent conduct was capable of damaging Class members' health (beyond contaminating their bodies); (iii) Defendants' *per se* negligent conduct was capable of damaging Class members' health (beyond contaminating their bodies); (iv) Defendants' public and private nuisances were capable of damaging Class members' health (beyond contaminating their bodies); and (v) Defendants' trespass was capable of damaging Class members' health (beyond contaminating their bodies).

142. The number of Class members is sufficiently numerous to make class action status the most practical method for Plaintiffs to resolve these common issues and secure redress for injuries sustained.

143. There are questions of law and fact raised by Plaintiffs' claims common to those raised by the Class they seek to represent. Such common questions predominate over questions affecting only individual members of the Class.

144. The violations of law and resulting harms alleged by Plaintiffs are typical of the legal violations and harms suffered by the different Class members.

145. As class representatives, Plaintiffs will fairly and adequately protect the interests of the Class members. Plaintiffs' counsel are unaware of any conflicts of interest between the class representatives and absent Class members with respect to the matters at issue in this litigation; the class representatives will vigorously prosecute the suit on behalf of the Class; and the class representatives are represented by experienced counsel. Plaintiffs are represented by attorneys with substantial experience and expertise in complex and class action litigation involving personal and property damage.

146. Plaintiffs' attorneys have identified and thoroughly investigated all claims in this action and have committed sufficient resources to represent the Class.

147. The maintenance of the action as a class action will be superior to other available methods of adjudication and will promote the convenient administration of justice. Moreover, the prosecution of separate actions by individual members of the Class could result in inconsistent or varying adjudications with respect to issues that are essential to Class members' claims against one or more of the Defendants.

148. Defendants have acted or failed to act on grounds generally applicable to Class members with respect to the additional class-wide issues, necessitating declaratory and injunctive relief for the Class.

COUNT I: NEGLIGENCE
BY ALL PLAINTIFFS AGAINST DEFENDANTS

149. Plaintiffs and the Class incorporate by reference the allegations set forth in all foregoing paragraphs, as if fully set forth herein.

150. Defendants owed Plaintiffs and the Class a duty to exercise reasonable care.

151. As alleged herein, Defendants, individually and collectively, breached their duty of reasonable care by allowing contaminants to be released into the Cape Fear River, as well as the drinking water and the airshed of New Hanover, Brunswick, Bladen, Cumberland, and Pender Counties.

152. Upon learning of the release of the contaminants in 1980, Defendants owed Plaintiffs and the Class a duty to act reasonably to remediate, contain, and eliminate the contamination before it injured Plaintiffs, the Class and their property and to act reasonably to minimize the damage to Plaintiffs, the Class and their property.

153. Defendants breached that duty by continuing to contaminate the local water supply and airshed, and by failing to act reasonably in providing Plaintiffs and the Class usable water. Furthermore, Defendants failed to take reasonable, adequate and sufficient steps or action to eliminate, correct, or remedy any contamination after it occurred.

154. Defendants further breached that duty by failing to timely notify Plaintiffs and the Class of the contamination of the Cape Fear River, as well as the airshed, and the drinking water of New Hanover, Brunswick, Bladen, Cumberland, and Pender Counties, and of the presence of contaminants in the ground, wells, homes, businesses, and rental properties of Plaintiffs and Class members.

155. As a result of Defendants' breaches of their duty to remediate the contamination, prevent the discharge of the contamination, and timely notify Plaintiffs and the Class of the contamination, Plaintiffs and the Class were forestalled from undertaking effective and immediate remedial measures, and Plaintiffs and the Class have expended and/or will be forced to expend significant resources to test, monitor, and remediate the effects of the Defendants' negligence for many years into the future.

156. Defendants' breach of their duty to exercise reasonable care proximately caused damage to Plaintiffs' and Class members' property. More specifically, as explained above, Defendants' conduct caused toxic PFCs to flow onto and into Plaintiffs' and Class members' land, wells, pipes, fixtures, and appliances. Plaintiffs' and Class members' real property is therefore less valuable, and Plaintiffs and Class members will have to spend money on remediation including cleaning and replacing pipes, fixtures, and appliances. Plaintiffs and Class members will also have to spend money to obtain bottled water, rather than obtaining water from clean, functioning pipes, and install and maintain filtration systems (including upkeep and maintenance) needed to avoid additional exposure to Defendants' PFCs.

157. In addition, Defendants' breach of their duty to exercise reasonable care proximately caused damage to Plaintiffs' bodies and was capable of proximately causing damage to Class members' bodies.

COUNT II: GROSS NEGLIGENCE
BY ALL PLAINTIFFS AGAINST DEFENDANTS

158. Plaintiffs and the Class incorporate by reference the allegations set forth in all foregoing paragraphs, as if fully set forth herein.

159. Defendants owed Plaintiffs and the Class a duty to exercise reasonable care. Upon learning of the release of the contaminants, Defendants owed Plaintiffs and the Class a duty to act reasonably to remediate, contain, and eliminate the contamination before it injured Plaintiffs, the Class and their property.

160. As alleged herein, Defendants, individually and collectively, caused drinking water with concentrations of GenX, and on information and belief other toxic chemicals, to be provided to Plaintiffs and the Class in contravention of drinking water standards. As such, Defendants, either with gross negligence, recklessly, willfully, wantonly, and/or intentionally, contaminated the Cape Fear River and the drinking water of New Hanover, Brunswick, Bladen, Cumberland, and Pender Counties, and contaminated the homes, businesses and rental properties of Plaintiffs and Class members.

161. Defendants owed Plaintiffs and the Class a duty to act with reasonable care in undertaking their obligations. As more fully described herein, Defendants breached their duties of care by failing to notify residents of New Hanover, Brunswick, Bladen, Cumberland, and Pender Counties that their water was contaminated with GenX and other toxic chemicals.

162. Defendants' conduct was so reckless as to demonstrate a substantial lack of concern for whether injury would result to Plaintiffs or the Class.

163. Defendants' breach of their duty to exercise reasonable care proximately caused damage to Plaintiffs' and Class members' property. More specifically, as explained above, Defendants' conduct caused toxic PFCs to flow onto and into Plaintiffs' and Class members' land, wells, pipes, fixtures, and appliances. Plaintiffs' and Class members' real property is therefore less valuable, and Plaintiffs and Class members will have to spend money on remediation including cleaning and replacing pipes, fixtures, and appliances. Plaintiffs and Class members will also have to spend money to obtain bottled water, rather than obtaining water from clean, functioning pipes, and install and maintain filtration systems (including upkeep and maintenance) needed to avoid additional exposure to Defendants' PFCs.

164. In addition, Defendants' breach of their duty to exercise reasonable care proximately caused damage to Plaintiffs' bodies and was capable of proximately causing damage to Class members' bodies.

COUNT III: NEGLIGENCE PER SE:
BY ALL PLAINTIFFS AGAINST DEFENDANTS

165. Plaintiffs and the Class incorporate by reference the allegations set forth in all foregoing paragraphs, as if fully set forth herein.

166. Defendants owed Plaintiffs and the Class a duty to follow standards of conduct set forth in laws, regulations, and permits, whose purpose is to ensure public safety.

167. By allowing GenX, and on information and belief related contaminants, to be released into the Cape Fear River as well as the drinking water and airshed of New Hanover, Brunswick, Bladen, Cumberland, and Pender Counties, Defendants violated federal and state public safety statutes and implementing regulations designed to safeguard human health and protect the environment, including, among others, the Clean Water Act, the Resource Conservation Recovery Act, the Safe Drinking Water Act, and the Solid Waste Disposal Act.

168. As a direct and proximate result of Defendants' violation of these standards, Plaintiffs and the Class have suffered and continue to suffer personal and property damage, as described above.

COUNT IV: PUBLIC AND PRIVATE NUISANCE:
BY ALL PLAINTIFFS AGAINST DEFENDANTS

169. Plaintiffs and the Class incorporate by reference the allegations set forth in all foregoing paragraphs, as if fully set forth herein.

170. Defendants' acts and omissions in discharging contaminants into the air and water supply in and around the Cape Fear River caused and continue to cause a substantial and unreasonable interference with Plaintiffs' and Class members' use and enjoyment of their properties and have materially diminished and continue to diminish the value of such properties.

171. As further detailed in the allegations herein, when Defendants discharged contaminants into the air and the water supply in and around the Cape Fear River, Defendants knew that the discharge would invade Plaintiffs' and Class members' interests in the use and enjoyment of their lands and properties. Additionally, Defendants' willful and wanton discharge of contaminants into the air and water supply in and around the Cape Fear River was negligent and/or reckless.

172. Defendants' substantial and unreasonable interference with the use and enjoyment of Plaintiffs' and Class members' properties and continuing substantial and unreasonable interference with such use and enjoyment constitutes a continuing private and public nuisance.

173. Defendants' contamination has injured Plaintiffs' and Class members' properties in a manner that is special to, and not shared by, the general public.

174. Defendants' nuisances proximately caused damage to Plaintiffs' and Class members' property. More specifically, as explained above, Defendants' conduct caused toxic

PFCs to flow onto Plaintiffs' and Class members' land, wells, pipes, fixtures, and appliances. Plaintiffs' and Class members' real property is therefore less valuable, and Plaintiffs and Class members will have to spend money on remediation including cleaning and replacing pipes, fixtures, and appliances. Plaintiffs and Class members will also have to spend money to obtain bottled water, rather than obtaining water from clean, functioning pipes, and install and maintain filtration systems (including upkeep and maintenance) needed to avoid additional exposure to Defendants' PFCs.

175. In addition, Defendants' nuisances proximately caused damage to Plaintiffs' bodies and was capable of proximately causing damage to Class members' bodies.

COUNT V: TRESPASS
BY ALL PLAINTIFFS AGAINST DEFENDANTS

176. Plaintiffs and Class members incorporate by reference the allegations set forth in all foregoing paragraphs, as if fully set forth herein.

177. Defendants' acts and omissions in willfully and wantonly discharging contaminants into the water supply in and around the Cape Fear River have resulted and continue to result in the release and threatened release of toxic chemicals at, under, onto, and into Plaintiffs' and Class members' bodies and properties.

178. The toxic chemicals present on Plaintiffs' and Class members' properties and in their bodies originating at Fayetteville Works were at all relevant times hereto, and continue to be, the property of Defendants.

179. The invasion and presence of the toxic chemicals at, under, onto, and into Plaintiffs' and Class members' properties and bodies was and continues to be without permission or authority from Plaintiffs, or any of the other Class members or anyone who could grant such permission or authority.

180. The presence and continuing presence of the toxic chemicals at Plaintiffs' and Class members' properties and in their bodies constitutes a continuing trespass.

181. Defendants' trespasses proximately caused damage to Plaintiffs' and Class members' property. More specifically, as explained above, Defendants' conduct caused toxic PFCs to flow onto Plaintiffs' and Class members' land, wells, pipes, fixtures, and appliances. Plaintiffs' and Class members' real property is therefore less valuable, and Plaintiffs and Class members will have to spend money on remediation including cleaning and replacing pipes, fixtures, and appliances. Plaintiffs and Class members will also have to spend money to obtain bottled water, rather than obtaining water from clean, functioning pipes, and install and maintain filtration systems (including upkeep and maintenance) needed to avoid additional exposure to Defendants' PFCs.

182. In addition, Defendants' trespasses proximately caused damage to Plaintiffs' bodies by violating their bodily integrity (*i.e.*, contaminating their bodies), thereby necessitating future medical expenses, including the costs of blood tests, to identify and treat their injuries. In addition, Defendants' trespasses were capable of proximately causing additional damages to Class members' bodies.

COUNT VI: UNJUST ENRICHMENT
BY ALL PLAINTIFFS AGAINST DEFENDANTS

183. Plaintiffs and Class members incorporate by reference the allegations set forth in all foregoing paragraphs, as if fully set forth herein.

184. Defendants failed to incur expenditures to limit or prevent the release of GenX and other toxic PFCs into the environment and prevent the contamination of Plaintiffs' and Class members' properties and household water supplies for a minimum of 33 years, failed to incur the costs to timely investigate the impacts on Plaintiffs and Class members and their properties, failed

to incur the costs to timely mitigate the impacts on Plaintiffs and Class members and their properties, and failed to incur costs to remediate the contaminated soil, dust and groundwater at Fayetteville Works. Defendants have been unjustly enriched by these and other failures to make expenditures to prevent the persons and properties of Plaintiffs and Class members from being contaminated with PFASs, GenX and Nafion byproducts.

185. Defendants have received a measurable monetary benefit by failing to make the necessary expenditures. It would be unconscionable and contrary to equity for Defendants to retain that benefit. Defendants are therefore liable to Plaintiffs and Class members.

PRAYER FOR RELIEF
PLAINTIFFS REQUEST THE FOLLOWING RELIEF FROM THE COURT:

- a. An order certifying a damages class pursuant to Fed. R. Civ. P. 23(b)(3) and an injunctive relief class pursuant to Fed. R. Civ. P. 23(b)(2);
- b. An injunctive order to remediate the harm caused by Defendants' conduct including, but not limited to: repairs of private property, funding of an epidemiological study to investigate the full scope of the health impact of GenX and other PFASs on the affected population, and establishment of medical monitoring to provide health care and other appropriate services to Class members for a period of time deemed appropriate by the Court;
- c. An order for an award of compensatory damages;
- d. An order for an award of punitive damages;
- e. An order for equitable relief;
- f. An order for pre-judgment and post-judgment interest;
- g. An order for an award of reasonable attorneys' fees and litigation expenses; and
- h. An order for all such other relief the court deems equitable.

DEMAND FOR TRIAL BY JURY

Plaintiffs demand a trial by jury as to all those issues triable as of right.

Dated: August 30, 2019

Respectfully submitted,

/s/ Theodore J. Leopold
Theodore J. Leopold
**COHEN MILSTEIN SELLERS
& TOLL PLLC**
2925 PGA Boulevard, Suite 220
Palm Beach Gardens, FL 33410
(561) 515-1400 Telephone
(561) 515-1401 Facsimile
tleopold@cohenmilstein.com

/s/ Jay Chaudhuri
Jay Chaudhuri
N.C. Bar No. 27747
**COHEN MILSTEIN SELLERS
& TOLL PLLC**
150 Fayetteville Street, Suite 980
Raleigh, NC 27601
(919) 890-0560 Telephone
(919) 890-0567 Facsimile
jchaudhuri@cohenmilstein.com

S. Douglas Bunch
Douglas J. McNamara
Jamie Bowers
Alison Deich
**COHEN MILSTEIN SELLERS
& TOLL PLLC**
1100 New York Ave., N.W., Suite 50
Washington, D.C. 20005
(202) 408-4600 Telephone
(202) 408-4699 Facsimile
dbunch@cohenmilstein.com
dmcnamara@cohenmilstein.com
jbowers@cohenmilstein.com
adeich@cohenmilstein.com

Vineet Bhatia
SUSMAN GODFREY, L.L.P.
1000 Louisiana Street, Suite 5100
Houston, TX 77002
(713) 651-3666 Telephone
(713) 654-6666 Facsimile
vbhatia@susmangodfrey.com

Stephen Morrissey
Jordan Connors
Steven Seigel
SUSMAN GODFREY, L.L.P.
1201 Third Ave., Suite 3800
Seattle, WA 98101
(206) 516-3880 Telephone
(206) 516-3883 Facsimile
smorrissey@susmangodfrey.com
jconnors@susmangodfrey.com
sseigel@susmangodfrey.com

Gary W. Jackson
N.C. Bar No. 13976
**THE LAW OFFICES OF
JAMES SCOTT FARRIN, P.C.**
280 South Mangum Street
Suite 400
Durham, NC 27701
(919)-688-4991 Telephone
(800)-716-7881 Facsimile
gjackson@farrin.com

Neal H. Weinfield
THE DEDENDUM GROUP
1956 Cloverdale Ave.
Highland Park, IL 60035
(312) 613-0800 Telephone
(847) 478-0800 Facsimile
nhw@dedendumgroup.com

Andrew Whiteman
WHITEMAN LAW FIRM
5400 Glenwood Avenue, Suite 225
Raleigh, NC 27612
(919) 571-8300 Telephone
(919) 571-1004 Facsimile
aow@whiteman-law.com

Attorneys for Plaintiff

CERTIFICATE OF SERVICE

I hereby certify that the undersigned electronically filed the foregoing document with the Clerk of Court using the ECF system, with notices of case activity to be generated and sent electronically to counsel of record who are registered to receive such service.

Dated: August 30, 2019

/s/ Steven Seigel
Steven Seigel

APPENDIX A

The PFCs identified in Plaintiffs' complaint include but are not limited to the following chemicals:

Chemical Name	CASN	Acronym / Common Name
2,3,3,3-Tetrafluoro-2- (1,1,2,2,3,3,3-heptafluoropropoxy)- propanoic acid	13252-13-6	PFPrOPrA/"GenX" (HFPO-DA)
2,3,3,3-Tetrafluoro-2-(pentafluoroethoxy) propanoic acid; Perfluoro-4-methoxybutanoic acid	267239-61-2; 8630-90-89-5	PEPA / PFMOBA
Hexanoic acid, 2,2,3,3,4,4,5,5,6,6-decafluoro-6-(trifluoromethoxy)-; Butanoic acid, 2,2,3,3,4,4-hexafluoro-4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethoxy]-	174767-10-3; 801212-59-9	PFECA-G
Nafion Byproduct 1	66796-30-3; 29311-67-9	PFESA/NB-1
Nafion Byproduct 2	749836-20-2	PFESA/NB-2
Perfluoro(3,5,7,9-tetraoxadecanoic) acid	39492-90-5	PFO4DA
Perfluoro(3,5,7-trioxaoctanoic) acid	39492-89-2	PFO3OA
Perfluoro(3,5-dioxahexanoic) acid	39492-88-1	PFO2HxA
Perfluoro-2- methoxypropanoic acid / Perfluoro-3-methoxypropanoic acid	13140-29-9; 377-73-1	PMPA / PFMOPrA
Perfluoro-2-methoxyacetic acid	674-13-5	PFMOAA
Perfluoro-2-methylethoxyacetic acid	151772-58-6	PFMOEA
Perfluoro-3-methoxypropanoic acid	377-73-1	PFMOPrA
Perfluoro-4-methoxybutanic acid	863090-89-5	PFMOBA
Perfluorobutanesulfonate	375-73-5	PFBS
Perfluorobutyric acid	375-22-4	PFBA
Perfluorodecanoic acid	335-76-2	PFDA
Perfluoroheptanoic acid	375-85-9	PFHpA
Perfluorohexadecanoic acid	67905-19-5	PFHxDA
Perfluorohexanesulfonate	355-46-4	PFHxS
Perfluorohexanoic acid	307-24-4	PFHxA
Perfluoro-n-dodecanoic acid	307-55-1	PFDoA
Perfluorononanoic acid	375-95-1	PFNA
Perfluoro-n-tetradecanoic acid	376-06-7	PFTeDA/PFTeA
Perfluoro-n-tridecanoic acid	72629-94-8	PFTTrDA/PFTnA
Perfluoro-n-undecanoic acid	2058-94-8	PFUDa/PFUnA
Perfluorooctadecanoic acid	16517-11-6	PFODA
Perfluorooctanesulfonate	1763-23-1	PFOS
Perfluorooctanoic acid	335-67-1	PFOA
Perfluoropentanesulfonate	2706-91-4	PFPeS
Perfluoropentanoic acid	2706-90-3	PFPeA
Sodium 2,2,4,4,6,6,8,8,10,10,12,12,12-tridecafluoro-3,5,7,9,11- pentaaxadodecanoate	39492-91-6	TAF n=4 / PF05DA
Sodium perfluoro-1-decanesulfonate	335-77-3	L-PFDS/PFDS

Attachment D

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF NORTH CAROLINA
SOUTHERN DIVISION**

BRENT NIX, individually and on behalf of all
others similarly situated,

Plaintiff,

v.

THE CHEMOURS COMPANY FC, LLC, THE
CHEMOURS COMPANY, E.I. DUPONT de
NEMOURS AND COMPANY, INC., E.I.
DUPONT CHEMICAL CORPORATION, ELLIS
H. MCGAUGHY, and MICHAEL E. JOHNSON,

Defendants.

Civil Action No. 7:17-CV-00189-D

ROGER MORTON, individually and on behalf of
all others similarly situated,

Plaintiff,

v.

THE CHEMOURS COMPANY FC, LLC, THE
CHEMOURS COMPANY, E.I. DUPONT de
NEMOURS AND COMPANY, INC., E.I.
DUPONT CHEMICAL CORPORATION, ELLIS
H. MCGAUGHY, AND MICHAEL E.
JOHNSON,

Defendants.

Civil Action No. 7:17-cv-00197-D

VICTORIA CAREY, MARIE BURRIS,
MICHAEL KISER, and BRENT NIX,
individually and on behalf of all others similarly
situated,

Plaintiffs,

v.

Civil Action No. 7:17-CV-00201-D

<p>E.I. DUPONT de NEMOURS AND COMPANY and THE CHEMOURS COMPANY FC, LLC,</p> <p>Defendants.</p>	
<p>CAPE FEAR PUBLIC UTILITY AUTHORITY, BRUNSWICK COUNTY, LOWER CAPE FEAR WATER & SEWER AUTHORITY, and TOWN OF WRIGHTSVILLE BEACH,</p> <p>Plaintiff,</p> <p>v.</p> <p>THE CHEMOURS COMPANY FC, LLC, E.I. DU PONT de NEMOURS AND COMPANY, and THE CHEMOURS COMPANY,</p> <p>Defendants.</p>	<p>Civil Action No. 7:17-CV-00195-D Civil Action No. 7:17-CV-00209-D</p>
<p>JAMES S. DEW, <i>et al.</i>,</p> <p>Plaintiffs,</p> <p>v.</p> <p>E.I. DUPONT de NEMOURS AND COMPANY, <i>et al.</i>,</p> <p>Defendants.</p>	<p>Civil Action No. 5:18-CV-0073-D</p>

**STIPULATION AND ORDER GOVERNING THE EXCHANGE
OF CONFIDENTIAL MATERIAL**

IT IS HEREBY STIPULATED AND AGREED, by and among Plaintiffs and Defendants (each of whom individually is referred to herein as a “Party,” and collectively, the “Parties”), by and through their undersigned counsel, pursuant to Rule 26(c) of the Federal Rules of Civil Procedure and Rule 502 of the Federal Rules of Evidence, that:

1. Information produced in this action, including deposition testimony and exhibits, documents produced in response to requests for production or subpoenas, electronically

stored information, responses to interrogatories and requests for admission, sampling and analytic data, and any other kind of discovery information (collectively, “Discovery Material”) are to be used solely for this litigation, except as set forth below.

2. Any Party, or individual or entity who produces any information in the above captioned action, may designate any information produced in this action, including deposition testimony and exhibits, documents produced in response to requests for production or subpoenas, electronically stored information, responses to interrogatories and requests for admission, sampling and analytic data, and any other kind of discovery information (collectively, “Discovery Material”), as:

- a. “Confidential” if, in good faith, the Party or individual or entity producing the Discovery Material (the “Producing Party”) believes (a) the material contains non-public, proprietary or commercially sensitive information; (b) the material requires the protections provided in this Stipulation and Order to prevent unreasonable annoyance, expense, disadvantage or prejudice to any person or entity; (c) the material contains personally identifying information of any individual, including but not limited to social security numbers and financial account numbers; (d) the material contains any other information of a personal or intimate nature regarding any individual; (e) the material contains information for which applicable agreements, regulations, or laws restrict public disclosure; or (e) the material contains any other category of information hereinafter given confidential status by the Court.

- b. “Highly Confidential” if, in good faith, the Producing Party believes any document, or any portion thereof, which a Producing Party or nonparty believes to be so extremely sensitive that disclosure of such information would create a substantial risk of serious harm that could not be avoided by less restrictive means.

3. The designation of Discovery Material as “Confidential” or “Highly Confidential” for the purposes of this Stipulation and Order shall be made in the following manner: (a) in the case of deposition or other pretrial testimony and any exhibits to said testimony, a Party shall either (i) make a statement on the record at the time of the testimony; or (ii) send within a reasonable period of time a written notice to counsel for all Parties to this litigation indicating the portions of the testimony and exhibits to which the “Confidential” or “Highly Confidential” designation applies; and in both of the foregoing instances, the Producing Party shall direct the court reporter to affix the legend “Confidential” or “Highly Confidential” to the first page and all designated portions of the transcript and exhibits, including all copies thereof; (b) in the case of responses to interrogatories and requests for admission, the Producing Party shall (i) state in the main body of responses that the interrogatory or request for admission at issue requests “Confidential” or “Highly Confidential” information, (ii) set forth the response to the interrogatory or request for admission at issue in an addendum attached to the main body of responses and (iii) affix the legend “Confidential” or “Highly Confidential” to each page of that addendum; (c) in the case of Discovery Materials produced on videotape, CD, DVD, external hard drive, or other electronic storage medium, the Producing Party shall affix the legend “Confidential” or “Highly Confidential” to the outside of such electronic storage medium or to each file, page or unit of electronically stored material; and (d) in the case of Discovery Materials produced

in hard copy, the Producing Party shall affix the legend “Confidential” or “Highly Confidential” to each page so designated.

4. If at any time prior to the trial of this action, a Party determines that some portion[s] of Discovery Material previously produced by that or any other party without limitation should be designated as “Confidential” or “Highly Confidential,” the Party may so designate by so apprising all Parties to the litigation in writing, and such designated portion[s] will thereafter be treated as Confidential or Highly Confidential Material under this Stipulation and Order. The delay in designating a document as “Confidential” or “Highly Confidential” shall not be deemed to have effected a waiver of any of the protections of this Stipulation and Order.

5. A Party may designate Discovery Material produced by a non-party as “Confidential” or “Highly Confidential” within thirty (30) days of receiving such material by providing written notice of the designation to all Parties to the litigation and to the producing non-party. Until such time period expires, all materials produced by the non-party shall be treated as Confidential Material. Any Party designating Discovery Material produced by a non-party as “Confidential” or “Highly Confidential” shall have a good faith basis to believe that the Discovery Material meets the criteria for Confidential or Highly Confidential Material set forth in paragraph 1.

6. Any Discovery Material designated Confidential or Highly Confidential, information derived therefrom, or any other documents or materials reflecting or disclosing any Confidential or Highly Confidential Material may only be used for the prosecution or defense of the above-captioned action, or any appeal therefrom, and shall not be used for any other purpose whatsoever, including but not limited to, any business or commercial purpose, for dissemination to the media or the public, or in connection with any other judicial, administrative or arbitral proceeding, except as set forth below.

7. Confidential Material may be disclosed, in all cases only in accordance with the provisions of this Stipulation and Order, only to:

- a. the Court and Court personnel, as appropriate;
- b. witnesses, deponents or persons whom a Party's counsel believes in good faith may be deponents or trial fact witnesses, and their counsel;
- c. each named Party and its employees, officers, and directors, provided that such persons are assisting the Party with this litigation and agree to be subject to this order;
- d. between Plaintiffs and Plaintiffs' counsel in any of the above-captioned actions to any of the other Plaintiffs and Plaintiffs' counsel in any of the above-captioned actions;
- e. each person identified on the face of the Confidential Material as an author or intended recipient (including by copy) thereof in whole or in part, or each person to whom counsel reasonably and in good faith believe that the original or a copy of such Confidential Material was sent or otherwise made available prior to this litigation;
- f. outside vendors such as court reporters, videographers, litigation support personnel, electronic discovery services, trial preparation services, or duplicating services, retained by the Court or by a party in connection with this litigation, provided they sign the certification attached as Exhibit A;
- g. counsel for the Parties, including in-house and outside counsel, legal assistants and other staff;

- h. experts or outside consultants, including necessary staff, retained by a Party or its counsel in connection with this litigation;
- i. insurance companies or other indemnitors for the named Parties which are providing coverage for claims in this matter and/or their in-house or outside counsel;
- j. as necessary to meet legal and/or regulatory obligations, including a court order requiring such disclosure; and
- k. any other person only by written consent of the Producing Party or upon order of the Court and on such conditions as may be agreed upon or ordered, but such consent will not be unreasonably withheld.

8. Highly Confidential Material may be disclosed, in all cases only in accordance with the provisions of this Stipulation and Order, only to:

- a. outside counsel for the parties and employees of such counsel who have responsibility for the action, provided that such individuals do not regularly participate in the commercial business activities of the party;
- b. the Court and its personnel;
- c. Plaintiffs and Plaintiffs' counsel in any of the above-captioned actions to any of the other Plaintiffs and Plaintiffs' counsel in any of the above-captioned actions;
- d. court reporters and recorders engaged for depositions;
- e. persons specifically engaged for the limited purpose of making copies of documents or organizing or processing documents, including outside

vendors hired to process electronically stored documents, provided they sign the certification attached as Exhibit A to this Order;

- f. consultants, investigators, or experts employed by a party or counsel for a party to assist in the preparation and trial of this action but only after such persons have completed the certification contained in Exhibit A to this Order;
- g. during depositions or testimony, (i) a witness who is an officer, director, or employee of the Producing Party or is testifying for the Producing Party pursuant to Fed. R. Civ. P. 30(b)(6); or (ii) a witness who was formerly an officer, director or employee of the Producing Party, if the document, information or material was in existence during the period of that person's employment by the Producing Party, and if the witness had access to the document during his or her employment by the Producing Party; or (iii) otherwise as agreed in writing by the Parties or ordered by the Court. Unless otherwise ordered by the Court, witnesses who are shown Confidential or Highly Confidential Material are entitled to review and retain, subject to the limitations described in paragraph 10, a copy of their deposition transcript and all exhibits. Pages of transcribed testimony or exhibits to depositions that are designated as Highly Confidential Material must be separately bound by the court reporter and may not be disclosed to anyone except as permitted under this Order.
- h. the author or recipient of the document (not including a person who received the document solely in the course of litigation);

- i. any person who is referenced in the document or whose conduct is purported to be identified in the document, provided that such person has completed the certification contained in Exhibit A to this Order;
- j. as necessary to meet legal and/or regulatory obligations, including a court order requiring such disclosure; and
- k. other persons only by written consent of the Producing Party or upon order of the Court and on such conditions as may be agreed or ordered, but such consent shall not be unreasonably withheld.

9. In the avoidance of doubt, nothing in this Stipulation or Order shall preclude a party from introducing into evidence at a hearing or trial any Confidential or Highly Confidential Material that is otherwise admissible under the Federal Rules of Evidence. At trial or evidentiary hearings, the parties agree that the Court may take such measures as the Court deems appropriate to protect the claimed Confidential or Highly Confidential document or information sought to be admitted.

10. Every person or entity given access to Confidential or Highly Confidential Material, or information derived therefrom or any other documents or materials reflecting or disclosing any Confidential or Highly Confidential Material, shall be advised that it is being disclosed pursuant and subject to the terms of this Stipulation and Order and may not be disclosed by any person or entity other than pursuant to the terms hereof. All persons and entities listed in paragraph 7 subsections (b), (f), (h), (i), and (k) and paragraph 8 subsections (d), (e), (f), (g), (h), (i), and (k) to whom a Party provides access to Confidential or Highly Confidential Material, information derived therefrom or any other documents or materials reflecting or disclosing any Confidential or Highly Confidential Material, shall execute a copy of the certification attached hereto as Exhibit A before such access is provided and be advised that he or she will be subject to the Stipulation and Order. Any report or

other work product created by an expert and/or consultant which relies on or incorporates any Discovery Material that is designated as “Confidential” or “Highly Confidential,” in whole or in part, shall be designated and treated as “Confidential” or “Highly Confidential” by the Party responsible for its creation.

11. The Parties agree that should a Party wish to request to use some part of the Discovery Material produced by another Party for some purpose that is not permitted under this protective order, counsel for the requesting Party shall notify the counsel for the Producing Party in a confidential writing and detail the specific reason for the request, its duration and to whom the disclosure of Discovery Materials is sought. The requesting Party shall use best efforts to narrowly tailor the scope, timing and intended recipient, and the recipient shall execute, in advance of the requested disclosure, a written undertaking to be bound by this protective order. The Producing Party shall respond to the request within ten (10) business days, and such request shall not be unreasonably denied. If the Parties are unable to reach agreement on such a request of Discovery Materials described herein, the Parties agree to submit the dispute to the Court.

12. Confidential or Highly Confidential Materials shall, if filed with or presented to the Court, be filed under seal unless otherwise ordered by the Court. Before filing any information that has been designated Confidential or Highly Confidential Material with the Court, or any pleadings, motions or other papers that disclose any such information, counsel shall confer with counsel for the party that produced the information so designated about how it should be filed. If the party that produced the information so designated desires that the materials be filed under seal, then the filing party shall file the materials in accordance with Local Civil Rule 79.2, with notice served upon the Producing Party. The filing of the materials under seal shall not be binding on the Court, however. Within 10 days of service of such notice, the party desiring that the materials be maintained under seal

shall file with the Court a Motion to Seal and supporting memorandum of law specifying the interests which would be served by restricting public access to the information. The party that initially filed the materials need not file any such Motion to Seal or otherwise defend another party's desire that the materials remain sealed. The Court will grant the Motion to Seal only after providing adequate notice to the public and opportunity for interested parties to object, after carefully weighing the interests advanced by the movant and those interests favoring public access to judicial documents and records, and upon finding that the interests advanced by the movant override any common law or constitutional right of public access which may attach to the information. Documents submitted under seal in accordance with this paragraph will remain under seal pending the Court's ruling. If the party desiring that the information be maintained under seal does not timely file a Motion to Seal, then the materials will be deemed unsealed, without need for order of the Court.

13. In the event that any Confidential or Highly Confidential Material is used in any court proceeding in this litigation or any appeal therefrom, said Confidential or Highly Confidential Material shall not lose its status as "Confidential" or "Highly Confidential" through such use. Counsel shall confer in good faith regarding any additional procedures necessary to protect the confidentiality of such Confidential or Highly Confidential Material used in the course of any court proceedings, except that a) such Confidential or Highly Confidential Material shall be allowed to be used at trial, pursuant to paragraph 9 hereof; and b) material filed under seal with the Court, according to the Court's procedures governing the filing of materials under seal, shall be exempt from such requirement.

14. Any Party may challenge, at any time, the designation of material as "Confidential" or "Highly Confidential" pursuant to the procedures outlined in this paragraph. The Party seeking to challenge such a designation shall contact the designating Party in a good faith effort to resolve the dispute. In the absence of the Parties coming to an agreement, the Producing Party shall file a motion

to maintain the “Confidential” or “Highly Confidential” designation within twenty-five (25) days of receiving written notice of a challenge to such “Confidential” or “Highly Confidential” designation. The Producing Party has the burden to show good cause for the “Confidential” or “Highly Confidential” designation. Should any such motion be filed, the motion shall be filed with the Court under seal. Until otherwise ordered by the Court, such material shall remain “Confidential” or “Highly Confidential.”

15. Any person or entity having received Confidential or Highly Confidential Material (the “Recipient”) shall take all due precautions to prevent any disclosure of such Confidential or Highly Confidential Material other than pursuant to the provisions of this Stipulation and Order. The Recipient shall maintain the Confidential or Highly Confidential Material in a secure and safe area and shall exercise the same standard of due and proper care with respect to the storage, custody, use, and/or dissemination of such material as is exercised by the Recipient with respect to its own confidential material. Confidential or Highly Confidential Material shall not be copied, reproduced, summarized, extracted, or abstracted, except to the extent that such copying, reproduction, summarization, extraction, or abstraction is reasonably necessary for the conduct of this lawsuit. All such copies, reproductions, summarizations, extractions, and abstractions shall be subject to the terms of this Stipulation and Order and labeled in the same manner as the Confidential or Highly Confidential Material on which they are based. In the event the Recipient of any electronic Discovery Material generates any electronic copy, hard copy, transcription, or printout from any non-paper media designated “Confidential” or “Highly Confidential,” the Recipient must treat each copy, transcription, or printout as “Confidential” or “Highly Confidential.”

16. Confidential or Highly Confidential Material which is disclosed in contravention of the provisions of this Stipulation and Order (through inadvertence or otherwise) shall continue to

be protected by the provisions hereof. Upon learning of the disclosure of Confidential or Highly Confidential Material in contravention of the provisions of this Stipulation and Order, the person or entity that made the disclosure promptly shall: (i) give written notice of the disclosure to the Producing Party, which notice shall include a specific description of the improperly disclosed Confidential or Highly Confidential Material; (ii) give written notice to the recipient of the improperly disclosed Confidential or Highly Confidential Material (the "Improper Recipient"); (iii) provide the Improper Recipient with a copy of this Stipulation and Order and request that the Improper Recipient sign a copy of the certification attached hereto as Exhibit A; (iv) give written notice of the Improper Recipient's response to the Producing Party; (v) make reasonable good faith efforts to retrieve the improperly disclosed Confidential or Highly Confidential Material and all copies thereof (including summaries, excerpts, notes and any other information derived therefrom); and (vi) give written notice to the Producing Party of the result of such efforts. The Producing Party's rights and remedies with respect to any such improper disclosure are hereby reserved.

17. If the Recipient of Discovery Materials, Confidential or Highly Confidential Material: (a) is subpoenaed in another action, (b) is served with a discovery demand as a party in another action, or (c) is served with any other legal process by a non-party to this litigation, seeking Confidential or Highly Confidential Material, the Recipient shall give actual written notice, by hand, electronic mail or facsimile transmission, within five (5) business days of receipt of such subpoena, demand, legal process to the Producing Party's counsel. The Recipient shall also immediately furnish to the Producing Party's counsel a copy of the subpoena, demand, legal process and shall maintain the confidentiality of the Confidential or Highly Confidential Material so that the Producing Party may seek a protective order or other relief precluding disclosure. Should the person seeking access to the Discovery Material, Confidential or Highly Confidential Material take any action against the Recipient

to enforce such subpoena, demand, other legal process, the Recipient shall respond by setting forth the existence of this Stipulation and Order. Nothing herein shall be construed as requiring the Recipient or anyone else covered by this Stipulation and Order to challenge or appeal any order requiring production of Confidential Material, to become subject to any penalties for noncompliance with any legal process or order, or to seek any relief from this Court.

18. This Stipulation and Order has no effect upon, and shall not apply to, the Producing Party's use of its own Confidential or Highly Confidential Material for any purpose. Nothing herein shall impose any restrictions on the use or disclosure, by a Party, of any document, material or information designated as "Confidential" or "Highly Confidential" that was obtained lawfully by such Party independently of the discovery proceedings in this litigation. The burden shall be on the Party asserting that the document, material or information was obtained independently to establish that fact. Notwithstanding the foregoing, information or data derived from sampling that was conducted on property not owned or operated by Defendants is not Confidential or Highly Confidential Material.

19. The Parties shall comply with their ethical and legal obligations concerning the actual or apparent inadvertent production of privileged or protected information consistent with Rule 26(b)(5)(B) of the Federal Rules of Civil Procedure and Federal Rule of Evidence 502(d). Disclosure of information subject to the attorney-client privilege or work-product doctrine or any other applicable privilege or immunity ("Privileged Material") shall not be deemed a waiver in whole or in part of the privilege or work-product protection or other applicable immunity, either as to the specific information disclosed or as to the same or related subject matter in the instant litigation or any other federal or state proceeding. If a Party has produced Discovery Material that it subsequently claims is Privileged Material, the receiving party (the "Party Receiving Privileged Material"), upon written or oral request, shall within five (5) business days return it, including all copies, and promptly destroy any notes

concerning it. The Party Receiving Privileged Material may not refuse to return the material. Upon receipt of the returned materials, the Producing Party shall within five (5) business days provide a written good faith explanation of the basis for the privilege claim or claim of immunity. If the Party Receiving Privileged Material wants to challenge the claim of inadvertent or unintentional production or the claim of privilege or immunity from disclosure, it must first return the material, then confer and provide written notice to the Producing Party identifying with particularity the reasons for the challenge. If the parties cannot resolve the dispute within a reasonable time, the Party Receiving Privileged Material may move the Court for an appropriate order. The disputed material shall be treated as privileged until a ruling on such motion or other resolution of the dispute.

20. Upon identification of any Discovery Material that, on its face, appears to be covered by any applicable privilege or immunity from disclosure, the recipient of such Discovery Material shall provide prompt notice of the production of that material to the Producing Party, to afford the Producing Party the opportunity to designate the material as Privileged Material within five (5) business days. Upon such designation by the Producing Party, the Party Receiving Privileged Material must return all copies of the Privileged Material and destroy any notes concerning it subject to the terms of Paragraph 20.

21. This Stipulation and Order shall survive termination of this litigation. Within sixty (60) days of the entry of an order, judgment or decree finally disposing of this litigation, including all appeals in which Discovery Materials, Confidential or Highly Confidential Material is permitted to be used, all persons or entities having received Discovery Materials, Confidential or Highly Confidential Material shall either: (a) return all Discovery Materials, Confidential or Highly Confidential Material and all copies thereof (including summaries and excerpts) to counsel for the Producing Party; or (b) destroy all Discovery Materials, Confidential or Highly Confidential Material and all copies thereof

(including summaries and excerpts) and certify that fact to the Producing Party. Outside counsel for the Parties to this litigation shall be entitled to retain court papers and attorney work product (including work product containing or incorporating Discovery Materials, Confidential or Highly Confidential Material), provided that such outside counsel, and employees of such outside counsel, shall not disclose such court papers or attorney work product to any person except pursuant to court order or agreement with the Producing Party. All materials returned to the Parties or their counsel by the Court likewise shall be disposed of in accordance with this paragraph. Notwithstanding the above, counsel for Cape Fear Public Utility Authority, Brunswick County, Lower Cape Fear Water & Sewer Authority, and Town of Wrightsville Beach shall retain a copy of the Discovery Materials, and shall either return or destroy all Discovery Materials from Defendants six years after the final disposition of this litigation, and certify that fact to the Producing Party, in accordance with this paragraph.

22. This Court shall retain jurisdiction over all persons and entities subject to this Stipulation and Order to the extent necessary to enforce any obligations arising hereunder or to impose sanctions for any contempt thereof.

23. This Stipulation and Order shall not be construed as waiving any right to assert an objection based on privilege, relevance, over-breadth, undue burden, or on any other grounds to the production of any material sought in a discovery request. Access to all requested materials (whether designated as “Confidential,” “Highly Confidential” or not) shall only be as provided by the relevant discovery rules and other applicable law.

24. Nothing in this Stipulation and Order prevents any party or other person from objecting to discovery that it believes to be otherwise improper or from seeking modification of this Stipulation and Order, including further provisions for categories of documents requiring heightened

protection. No modifications will be made except by advance written agreement of all parties or by order of the Court upon motion by any Party.

25. Neither this Stipulation and Order nor any of the procedures described above affects or constitutes a waiver of any party's right to object to the relevancy, admissibility, or discoverability of any information or document or to seek an order that discovery may be had only subject to appropriate limits or restrictions, as provided by the Federal Rules of Civil Procedure, the Federal Rules of Evidence, the Local Rules of this Court, or other applicable rules or law.

26. This Stipulation and Order may be executed in counterparts which together shall constitute one document. Any party added by name to this case after the "so ordering" of this Stipulation and Order shall be bound by it without having to execute it.

Dated: September 6, 2019.

Respectfully submitted,

<p><u>/s/ Kenneth J. Reilly</u> John K. Sherk III CA State Bar No. 295838 SHOOK, HARDY & BACON, L.L.P One Montgomery, Suite 2600 San Francisco, CA 94104 Telephone: (415) 544-1900 Facsimile: (415) 391-0281 jsherk@shb.com</p> <p>Kenneth J. Reilly FL State Bar No. 157082 SHOOK, HARDY & BACON, L.L.P 201 S. Biscayne Blvd. 3200 Miami Center Miami, FL 33131 Telephone: (305) 960-6907 Facsimile: (305) 385-7470 kreilly@shb.com</p> <p>Jonathan D. Sasser Stephen D. Feldman ELLIS & WINTERS LLP P.O. Box 33550 Raleigh, NC 27636 Telephone: (919) 865-7000 Facsimile: (919) 865-7010 jon.sasser@elliswinters.com stephen.feldman@elliswinters.com</p> <p><i>Attorneys for Defendants</i></p>	<p><u>/s/ Theodore J. Leopold</u> Theodore J. Leopold COHEN MILSTEIN SELLERS & TOLL PLLC 2925 PGA Boulevard Suite 220 Palm Beach Gardens, FL 33410 Telephone: (561) 515-1400 Facsimile: (561) 515-1401 tleopold@cohenmilstein.com</p> <p>Jay Chaudhuri N.C. Bar No. 27747 COHEN MILSTEIN SELLERS & TOLL PLLC 150 Fayetteville Street Suite 980 Raleigh, NC 27601 Telephone: (919) 890-0560 Facsimile: (919) 890-0567 jchaudhuri@cohenmilstein.com</p> <p>Andrew Whiteman N.C. Bar No. 9523 WHITEMAN LAW FIRM 5400 Glenwood Ave. Suite 225 Raleigh, NC 27612 Telephone: (919) 571-8300 Facsimile: (919) 571-1004 aow@whiteman-law.com</p> <p>S. Douglas Bunch Douglas J. McNamara Jamie Bowers Alison Deich COHEN MILSTEIN SELLERS & TOLL PLLC 1100 New York Ave., N.W. Suite 500 Washington, D.C. 20005 Telephone: (202) 408-4600 Facsimile: (202) 408-4699 dbunch@cohenmilstein.com dmcnamara@cohenmilstein.com jbowers@cohenmilstein.com</p>
---	---

adeich@cohenmilstein.com

Vineet Bhatia
SUSMAN GODFREY, L.L.P.
1000 Louisiana Street
Suite 5100
Houston, TX 77002
Telephone: (713) 651-3666
Facsimile: (713) 654-6666
vbhatia@susmangodfrey.com

Stephen Morrissey
Jordan Connors
Steven Seigel
SUSMAN GODFREY, L.L.P.
1201 Third Ave.
Suite 3800
Seattle, WA 98101
Telephone: (206) 516-3880
Facsimile: (206) 516-3883
smorrissey@susmangodfrey.com
jconnors@susmangodfrey.com
sseigel@susmangodfrey.com

Gary W. Jackson
N.C. Bar No. 13976
**THE LAW OFFICES OF
JAMES SCOTT FARRIN, P.C.**
280 South Mangum Street
Suite 400
Durham, NC 27701
Telephone: (919) 688-4991
Facsimile: (800) 716-7881
gjackson@farrin.com

Neal H. Weinfield
THE DEDENDUM GROUP
1956 Cloverdale Ave.
Highland Park, IL 60035
Telephone: (312) 613-0800
Facsimile: (847) 478-0800
nhw@dedendumgroup.com

*Attorneys for Victoria Carey, Marie
Burris, Brent Nix, and Michael
Kiser*

/s/ Joseph A. Ponzi

Joseph A. Ponzi

N.C. Bar No. 36999

George W. House

N.C. Bar No. 7426

William P. H. Cary

N.C. Bar No. 7651

V. Randall Tinsley

N.C. Bar No. 14429

**BROOKS, PIERCE, McLENDON,
HUMPHREY & LEONARD, LLP**

Post Office Box 26000

Greensboro, NC 27420-6000

Telephone: (336) 373-8850

Facsimile: (336) 232.9114

jponzi@brookspierce.com

ghouse@brookspierce.com

wcary@brookspierce.com

rtinsley@brookspierce.com

***Counsel for Plaintiff Cape Fear
Public Utility Authority***

/s/ M. Cristina Sanchez

M. Cristina Sanchez

Scott Summy

N.C. Bar No. 27171

Cary McDougal

Stephen Johnston

Brett Land

BARON & BUDD, P.C.

3102 Oak Lawn Ave.

Suite 1100

Dallas, TX 75219-4281

Telephone: (214) 521-3605

Facsimile: (214) 520-1181

csanchez@baronbudd.com

ssummy@baronbudd.com

cmcdougal@baronbudd.com

sjohnston@baronbudd.com

bland@baronbudd.com

J. Harold Seagle

N.C. Bar No. 8017

SEAGLE LAW, PLLC

P.O. Box 15307
Asheville, NC 28813
Telephone: (828) 545-7777
Facsimile: (828) 545-7701
haroldseagle@charter.net

***Attorneys for Plaintiffs Brunswick
County, Lower Cape Fear Sewer &
Water Authority, and Town of
Wrightsville Beach***

Dated: September 19, 2019



Robert T. Numbers, II
United States Magistrate Judge

EXHIBIT A: CERTIFICATION

I, _____, a _____ of _____, hereby certify that I have read the attached Stipulation and Order Governing the Exchange of Confidential or Highly Confidential Material, dated __, 2019. I hereby agree to be bound by the terms of the Stipulation and Order. I will not divulge any information, documents, or copies of Confidential or Highly Confidential Information obtained pursuant to such Stipulation and Order, or the contents of such documents, to any person other than those specifically authorized by the Stipulation and Order. I will not copy or use such information or documents except for the purposes of this action and pursuant to the terms of the Stipulation and Order.

For purposes of enforcing the Stipulation and Order, I hereby agree to be subject to the jurisdiction of the United States District Court for the Eastern District of North Carolina. I understand that violation of the Stipulation and Order is may subject me to sanctions by the Court, including contempt.

Signature: _____

Dated: _____